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Abstract
RNA polymerase III transcription has been found to be abnormally elevated in 
many types of transformed and tumour cells. These rapidly growing cells 
demonstrate an increase in pol III transcripts and hence, an accumulation of 
protein above normal levels. The accretion of protein may lead to uncontrolled 
cell growth, a hallmark of cancer. Thus, the ability of pol III to increase a 
cell’s biosynthetic capacity links it with malignant growth. Therefore, 
experiments were conducted to assess whether pol III transcription could be 
regulated by decreasing transcription in mammalian cells.
Homo sapien and Mus musculus cell lines were investigated to consider three 
different methods for decreasing pol III transcription; targeting a subunit of 
the transcription machinery, Brfl, by small interfering RNA, targeting the 
polymerase with the specific drug tagetitoxin, and inducing a negative effector 
of pol III transcription, Mafl. Levels of pol III transcripts were decreased in 
response to transfection of Brfl siRNA, which also had a decreased effect on 
proliferation rates. When cells were treated with tagetitoxin during 
electroporation, pol III transcription also decreased. Induction of the pol III 
suppressor Mafl decreased pol III transcripts to varying degrees, although 
faults were found within this system. More significant data was obtained by 
the application of siRNA against Mafl, as well from the analysis of samples 
acquired from heterozygous Mafl cells. These results showed that decreasing 
Mafl allows for the deregulation of pol III and an increase in pol III 
transcription.
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1 Introduction
Chapter 1
Introduction
1 Introduction
1.1 Transcription
Gene expression is determined by which genes are transcribed. Transcription 
serves as the first step in gene expression, decoding a genome. During this 
essential process, DNA is copied into complementary RNA sequence by RNA 
polymerase. Because transcription is the first step in gene expression, it serves 
as the most common and important level of regulatory control. Transcriptional 
regulation is involved in biochemical processes such as a cell’s growth and 
development, serving to assist the cell in adapting to its changing environment. 
Deficient transcription can result in abundant defects in biological processes 
resulting in a multitude of disease states such as diabetes, cardiovascular 
hypertension, developmental abnormalities, and cancer.
1.2 Four nuclear eukaryotic RNA polymerases
Eukaryotes have four nuclear RNA polymerases (pols) which transcribe the 
nuclear genes, namely RNA polymerases I, II, III and a recently found single­
polypeptide nuclear RNA polymerase of mitochondrial origin, spRNAP-IV 
(pol IV) (Kravchenko et a l, 2005; Sentenac, 1985). The identities of pol I, pol 
II and pol III were found by their different elution from DEAE- Sephadex 
columns, as well as differing sensitivities to the toxin a-amanitin (Kedinger et 
al, 1970; Roeder and Rutter, 1969). Recently, it was revealed that pol IV 
expression originates from an alternative transcript of the mitochondrial RNA 
polymerase gene (POLMT) (KTavchenko et al, 2005). RNA polymerase I (pol 
I) synthesizes most of the ribosomal (r)RNA, comprising 28S, 18S and 5.8S 
ribosomal RNAs which are processed from the large 45 S RNA precursor 
molecule (pre-RNA). Pol I may be responsible for 70 to 80% of nuclear
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transcription in proliferating cells (White, 2001a). RNA polymerase II (pol II) 
produces the protein-encoding messenger (m)RNAs and most of the small 
nuclear (sn)RNAs which are involved in mRNA processing. RNA polymerase 
III (pol III) is responsible for 10 to 20% of all nuclear transcription and 
produces small, stable, untranslated RNAs. These genes are less than 400 
nucleotides in length and encode structural or catalytic RNAs (Schramm and 
Hernandez, 2002; White, 2001a) with important roles in cellular metabolism, 
including; transfer (t)RNAs, 5S rRNA, and VA RNAs which are encoded by 
adenovirus and used to direct translational machinery of an infected cell 
towards increased viral load (White, 2001a). 7SL RNA is also synthesized by 
pol III and is involved in intracellular protein transport as part of the signal 
recognition particle. Lesser characterised pol III products include U6 snRNA, 
HI and MRP RNAs involved in RNA transcript processing, 7SK, and RNAs 
encoded by the short interspersed repeat (SINE) gene families.
1.3 Class III genes
Genes transcribed by the nuclear eukaryotic RNA polymerases are grouped 
into classes, determined by which polymerase transcribes that particular set of 
genes. Therefore, templates transcribed by pols I, II, III are referred to as class 
I, II and III genes, respectively. A table of class III gene products is located 
below.
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Table 1.1 Summary stating gene products and function of class III genes.’
Product Function
tRNA Translational adaptor
5SrRNA Ribosomal component
U6 snRNA mRNA splicing
HI RNA RNase P component (tRNA processing)
MRP RNA rRNA splicing and mitochondrial DNA replication
7SLRNA Signal recognition particle component
7SKRNA Control of P-Tef-b and mRNA elongation
SINE transcripts Unknown, might perform a role in cellular stress responses
VARNA Translation control (adenovirus)
vault RNAs Component of cytoplasmic vault nucleoproteins
EBER RNAs Epstein-Barr virus translational control
* Adapted from White, 2001b.
1,3.1 tRNA
Apart from mitochondrial tRNA, a high level of structural conservation exists 
between tRNAs from prokaryotes and eukaryotes (Sharp et a t, 1984). In 
Saccharomyces cerevisiae and other eukaryotes, early tRNA processing 
components have been found in the nucleolus, suggesting that transcription of 
the tRNA genes might also be nucleolar (Thompson et a l , 2003). tRNA genes 
have transcripts that are processed to between 70 and 90 nucleotides, which 
serve as translational adaptors and enable amino acids to align according to the 
sequence of nucleotides in the mRNA (Alberts et a l, 2002). Accurate
1 Introduction
translation of mRNA into a polypeptide chain rests on the ability of a tRNA to 
read the three residue anti-codon sequence. Eukaryotic cells possess 50 to 100 
distinct tRNAs (Sharp et a l, 1984), however, the proportions of each tRNA 
species vary between cell type (Garel, 1976). Because each of the tRNA 
species has a similar structure, their individual nucleotide sequence creates a 
specificity that allows one tRNA to recognize only one amino acid. This 
amino acid is brought to the lengthening peptide chain only if it matches a 
complementary codon in the mRNA. Errors in this process occur at a 
surprisingly low rate of one mistake in 40,000 couplings, revealing the 
importance of this process and its control on protein synthesis (Alberts et a l , 
2002).
1.3.2 SSrRNA
The 120 nucleotide 5S rRNA is the smallest of the ribosomal RNAs, yet it is 
essential for all eukaryotic organisms, playing a critical role in translation 
(Wool, 1979). Although there are exceptions, the 5S rRNA gene is generally 
present in the common rRNA precursor in bacteria and archaea, but is 
independently transcribed by pol III in eukaryotes (Lafontaine and Tollervey, 
2001). Pre-ribosomal RNA is processed into mature rRNA species which are 
then transported into the nucleolus, both forms undergoing covalent 
modifications. After further transport to the cytoplasm, 5S rRNA is 
incorporated into the large ribosomal subunit which begins the formation of 
peptide bonds (Wool, 1979). In humans, cells contain 200- 300 5S rRNA 
genes, while Saccharomyces cerevisiae and Xenopus laevis contain 140 and 
over 200,000 copies, respectively (Consortium, 2001; Elion and Warner, 1984; 
Wolffe and Brown, 1988). InX. laevis, most 5S genes are only expressed in
5
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the oocyte to sustain rapid growth during development (Wolffe and Brown,
1988).
1.3.3 U6snRNA
U6, along with five other small nuclear ribonucleoproteins (snRNPs) and non­
small nuclear ribonucleoproteins, functions to remove pre-mRNA introns 
within the formed spliceosome (Hastings and Krainer, 2001). Through this 
process, pre-mRNA genes transcribed by pol II are extensively modified and a 
coding sequence compatible with translation is created. In yeast, U6 snRNA 
uses a metal ion that is required for the catalytic activity of this process (Yean 
et al, 2000). U6 is the smallest of the five snRNPs (106 nucleotides) and is 
the only component of the spliceosome that is not transcribed by pol II (Brow 
and Guthrie, 1988; Kunkel et a l, 1986).
1.3.4 HI and MRP RNAs
The gene coding for human HI RNA is only present in one to three copies per 
cell (Bartkiewicz et a l, 1989). This 369 nucleotide long molecule was first 
isolated from HeLa (human cervical carcinoma) cells (Bartkiewicz et al,
1989), and found to resemble the structure for the RNA subunit of RNase P
(Bartkiewicz et a l, 1989; Lee and Engelke, 1989). RNase P has endonuclease
activity and is involved in processing pre-tRNA (Lee and Engelke, 1989). HI
RNA exhibits some sequence homology to MRP RNA (Gold et a l, 1989), hoth
RNA subunits of these two enzymes sharing a highly conserved helical region,
P4 (Piccinelli et a l, 2005). While hoth components are involved in RNA
processing, RNase P is found in all phylogenetic domains and cleaves a pre-
tRNA to produce a mature 5’ end of the tRNA, while MRP is only found in
6
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eukaryotes and is important for rRNA processing, cleaving pre-rRNA to 5.8S 
rRNA.
1.3.5 7SL
7SL is a component of the signal recognition particle (SRP) that mediates co- 
translational insertion of secretory proteins into the endoplasmic reticulum. 
Only a few copies of the full length 7SL gene exist within the human nuclear 
genome, encoding for a highly conserved 300 nucleotide transcript (Ullu and 
Tschudi, 1984; Ullu and Weiner, 1984). 7SL serves as a scaffold protein in the 
SRP, which undergoes structural changes during the assembly of the signal 
recognition complex (Kuglstatter et al,, 2002).
1.3.6 7SK
7SK, a 330 nucleotide snRNA, was found to interact with the transcription 
elongation factor P-TEFb in a reversible manner which is transcription- 
dependent (Nguyen et a l, 2001). The 7SK-P-TEFh interaction contributes to 
an important feedback loop modulating the activity of pol II in which P-TEFb 
stimulates transcription of cellular and viral genes by phosphorylating the 
polymerase (Chen et a l, 2004). Phosphorylation of CDK9, a kinase 
comprising part of P-TEFb, is crucial for the 7SK-P-TEFb interaction.
1.3.7 SINEs
SINEs (short interspersed elements) include the mammalian Alu gene family, 
as well as the rodent B1 and B2 families, and range from 50 to 500 
nucleotides. It is estimated that 5% of the human genome consists of Alu
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repeats (-one million copies in the haploid genome), while B1 genes are 
present at 100,000 copies per haploid mouse genome (Bennett et a l, 1984; 
Consortium, 2001; Rudin and Thompson, 2001). Alu genes are most common 
in humans, while B1 and B2 families are most prevalent in rodents, B2 being 
rodent-specific. Alu genes are homologous to B1 genes (-80%) (Bennett et a l, 
1984), which are thought to be derived from 7SL RNA (Ullu and Tschudi, 
1984). B2 genes are believed to have evolved from tRNA (Schmid, 1998).
SINE sequences are retroelements, retroposons that are replicated through an 
RNA intermediate which is reverse transcribed, amplified and then integrated 
throughout the genome, accounting for their high prevalence (Williams et a l , 
2004). SINE functions are largely unknown; however, certain SINE transcripts 
have been found to be upregulated in a variety of stress conditions such as; 
heat shock (Allen et a l, 2004; Liu et a l, 1995), cisplatin treatment, etoposide 
and gamma radiation (Rudin and Thompson, 2001), cyclohexamide treatment 
(Liu et a l, 1995), and cells infected with various types of virus (Jang and 
Latchman, 1989; Panning and Smiley, 1993).
1.3.8 Viral RNAs
There are many viruses that contain short segments of coding region that signal 
pol III transcription of viral genomes. Pol III viral product VA RNA, which 
are encoded by adenovirus, divert the translational machinery of a virus 
infected cell towards efficient production of viral transcripts (White, 2001b). 
Pol III is essential in its role in adenovirus transcription as this allows the virus 
to rapidly multiply, producing high levels of transcripts at late stages of 
infection (Soderlund et a l, 1976). The Epstein-Barr virus (EBV) genome
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contains EBER-1 and EBER-2 genes that are also transcribed by the pol III 
transcription machinery. These small nuclear RNAs have regions of homology 
to VA genes and are 166 and 172 nucleotides long, respectively (Clarke et a l, 
1992; Rosa et a l, 1981). The EBV genome contains these genes, and EBERs 
have been found to play an oncogenic role in Burkitt’s lymphoma cells, 
showing an ability to repress the cell’s antiviral response as well as inducing 
growth in soft agar and the formation of tumours in mice (Romano et a l, 
1999).
1.3.9 Vault RNAs
Vault (v)RNAs ar e components of large cytoplasmic vault nucleoproteins with 
largely unknown functions and transcribed by pol III (Rome et a l, 1991). In 
humans there are four separate genes (hvgl-4) that encode similar vRNAs and 
vary in length from 86 to 142 nucleotides long (Kickhoefer et a l, 1998; Van 
Zon et ai., 2001). Recently, evidence of involvement in drug resistance has 
been discussed, but is under controversy (Mossink et a l, 2003). It was 
hypothesized that vaults could possibly contribute to drug resistance by 
transporting or sequestering drugs away from their intracellular targets.
1.4 Class III gene promoters
There are three types of promoter arrangements that are utilized by pol III 
(White, 2001b). The unusual feature of most class III promoters is the location 
of the sequence elements downstream of the transcription start site, lying 
within the transcribed region. These types of promoters are deemed type 1 and 
2. Class I and class II genes, transcribed by pols I and II, respectively, mostly
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consist of sequence elements upstream of the start site. Pol Ill’s type III 
promoter structure is more like that of class I and II genes, the sequence 
elements found upstream of the start site. A schematic of the three promoter 
types is depicted in Figure 1.1 and described in detail below.
1.4.1 Type I promoters
5S rRNA genes are the only pol III genes to utilize type I promoters. This 
promoter requires three internal elements: a highly conserved A-block (located 
between +50 and +64) an intermediate element (IE) (between +67 and +72) 
and a C-block (between +80 to +97) (Figure 1.1). Studies in % laevis have 
shown that spacing of the internal elements is important for efficient 
transcription, as alternations in the spacing of these elements has been found to 
reduce transcription activity and prevent formation of a stable initiation 
complex (Pieler et a l, 1987).
The region between the A-block and transcriptional start site is an important 
determinant of 5S rRNA expression, particularly when conditions are 
unfavourable for transcription (Keller et a l, 1990). Mutations within the A- 
and C- blocks abolish transcription, while the flanking sequences are more 
resilient to mutations (Keller et al, 1990; White, 2001a).
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Type I promoter
5S rRNA genes
t .
+ 1
Type II promoter
e.g. tRNA genes
+ 1
Type III promoter
e.g. vertebrate U6 genes
PSE
In
ft
+ 1
Figure 1.1 Three types of promoter structure that are 
utilized by pol III * The coloured boxes represent the promoter 
elements.
Abbreviations: IE, intermediate element; Tn, termination site; 
DSE, distal sequence element; PSE, proximal sequence element; 
TATA, TATA box. * Adapted from White, 2001b.
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The region between the A-block and transcriptional start site is an important 
determinant of 5S rRNA expression, particularly when conditions are 
unfavourable for transcription (Keller et al, 1990). Mutations within the A- 
and C- blocks abolish transcription, while the flanking sequences are more 
resilient to mutations (Keller et a l, 1990; White, 2001a).
1.4.2 Type II promoters
The most common promoter employed by pol III is the type II promoter, 
utilized by tRNA genes, the adenovirus VA genes, and many SINE gene 
families. Type II promoters are constructed of two lObp sequence blocks A- 
and B-, separated by 30 to 40bp (Galli et al, 1981). The A- block is 
homologous to the A- block sequence of type I promoters, functionally 
interchangeable in some species (Ciliberto et al, 1983). The location of A- 
blocks in type I and type II is different, however; in type I promoters the A- 
block lies ~50bp from the start site, while the type II promoter A- block lies at 
+10 to +20, much closer to the start site (Galli et a l, 1981). The location of 
the B- block can be extremely variable, a possible reason for this lying in the 
presence of small introns within the coding regions of some tRNA genes. 
Optimal binding of the A- and B- blocks occurs with genes that have an A- 
block and B- block at a distance of 30 to 60 base pairs, however a span of 365 
base pairs remains transcriptionally functional (Baker et a l, 1987; Fabrizio et 
al, 1987).
1.4.3 Type III promoters
Vertebrate type III promoters utilized by U6 snRNA, 7SK and MRP genes lack
any requirement for intragenic promoter elements (Das et a l, 1988; Kunkel
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and Pederson, 1989; Murphy et a l, 1987; Paule and White, 2000; Yuan and 
Reddy, 1991). This is unusual, as this type of promoter structure is more 
similar to that found in genes transcribed by pol I and II. The best 
characterised type III promoter is that of the U6 gene. Transcription of this 
gene requires a TATA box (located between -30 and -25), a proximal sequence 
element (PSE) (between -66 and -47) and a distal sequence element (DSE) 
(between -244 and -214) (Carbon et a l, 1987; Das et a l, 1988; Kunkel and 
Pederson, 1988; Kunkel and Pederson, 1989; Lobo and Hernandez, 1989). The 
pol Il-transcribed U2 snRNA gene and the U6 snRNA genes share 
commonality in that the U6 PSE and DSE are homologous and interchangeable 
(Kunkel and Pederson, 1988). An unusual anomaly lies in the ability of the U2 
gene (usually lacking a TATA box) to be transcribed by pol III when a TATA 
box is inserted and, inversely, crippling the U6 TATA box allows U6 to be 
transcribed by pol II (Lobo and Hernandez, 1989).
1.5 Transcription of class III genes
Before transcription can be initiated, the polymerase and many accessory 
factors, namely transcription factors, must be assembled onto the promoter. 
The process of transcription begins when a pre-initiation complex containing 
all the necessary factors is complete, proceeds with an elongation step, and 
terminates with the polymerase being recycled for further rounds of 
transcription.
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1.5.1 Assembly of transcription machinery on type II 
promoters
Due to the three different types of promoters utilized by pol III, there is a 
different requirement of transcription factors and the order in which they are 
brought to the promoter. Pol III has little specificity for the above promoter 
elements and therefore must employ specific transcription factor complexes to 
create a functional transcription initiation apparatus. Assembly on type II 
promoters will be discussed first (Figure 1.2), as it is the most commonly 
utilized promoter type, followed by the remaining promoters.
1.5.1.1 Transcription Factor IIIC (TFIIIC)
TFIIIC is one of the largest and most complicated transcription factors being 
studied (Geiduschek and Kassavetis, 2001; Paule and White, 2000). TFIIIC, a 
multi-subunit complex, recognizes the A- and B- blocks of both type I and type 
III promoters, binding simultaneously. In Saccharomyces, TFIIIC has been 
found to consist of two globular domains, each ~300kDa and composed of six 
subunits (Schultz et a l, 1989). In human cells, two major subunits have been 
separated chromatographically into two sub-complexes, TFIIIC 1 and TFIIIC2 
(Yoshinaga et al., 1987). Little is known concerning TFIIIC 1, although 
sedimentation analysis suggests a possible mass of 200kDa and is required for 
transcription activity (Kovelman and Boeder, 1992). TFIIIC2 is the best 
characterized of the TFIIIC subunits, with a total of five subunits, binding to 
the B- block promoter through its 220 kDa subunit (Geiduschek and 
Kassavetis, 2001). TFIIIC2 initially recognizes the type II promoter, and then 
recruits TFIIIC 1 and transcription factor IIIB (TFIIIB) (Figure 1.2).
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tDNA TFIIIC
TFIIIB
4 -
Tn
t -
Tn
Tn
Figure 1.2 Step-by-step assembly of pol III basal 
transcription machinery on a type 2 promoter.
TFIIIC is recruited first and binds to the A- and B- blocks 
simultaneously. TFIIIB is then bound to TFIIIC through 
protein-protein interactions, followed by the binding o f the 
polymerase. The transcription start site is noted as +1 and the 
termination site as Tn.
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TFIIIC subunits 63, 90 and 102 bind to Brfl (a subunit of TFIIIB), while 
TFIIIC63 and 102 binds to TATA-binding protein (TBP) (another TFIIIB 
subunit) (Hsieh et a l, 1999b; Hsieh et a l, 1999a). Binding of TFIIIC 1 and 
TFIIIB enhances and extends the protein footprint produced by TFIIIC2 to 
include the A- block (Wang and Boeder, 1998; Yoshinaga et a l, 1987). 
Photocrosslinking experiments have shown that the various subunits of TFIIIC 
span across the length of the entire gene, creating the appearance of a dumbbell 
when bound (Bartholomew et a l, 1990). Both TFIIIC 1 and TFIIIC2 are 
required for expression of 5S rRNA, VA and tRNA genes, while U6 and 7SK 
genes require TFIIIC 1 but not TFIIIC2 for transcription.
1.5.1.2 Transcription factor IIIB (TFIIIB)
TFIIIC serves to recruit TFIIIB to the promoter, TFIIIB being regarded as an 
extremely important factor in the pol III transcription system. TFIIIB is 
composed of at least three proteins in both Saccharomyces cerevisaie and 
humans: TBP, and two TBP-associated factors, currently known as TFIIB- 
related factor (Brfl) and B double prime (Bdpl). TFIIIB has heen shown to be 
an important target for cell cycle regulation in actively proliferating cells, 
functioning as a point of control by both tumour suppressors and transforming 
proteins, helping to determine a cell’s biosynthetic capacity (White, 1998). In 
yeast, TFIIIB alone assembled upstream of the transcription start site can direct 
multiple rounds of transcription on the tRNA and U6 snRNA genes (Dieci and 
Sentenac, 2004).
TBP is a 34kDa general transcription factor utilized by the transcription 
machineries of pol I, II and III (Cormack and Struhl, 1992; White and Jackson,
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1992). In the case of pol III, the involvement of TBP was unexpected because 
most class III genes lack TATA boxes. The first indication that TBP 
functioned with TFIIIB in an active transcription complex was uncovered 
when a population of TBP molecules copurified with TFIIIB activity in yeast 
(Margottin et a l, 1991), later found to be bound to Brf, which can be bound in 
the absence of DNA through a conserved region of TBP (Colbert et a l, 1998; 
Shen et a l, 1998).
The 160kDa subunit Bdpl was first found to copurify with Brfl (Kassavetis et 
a l, 1991b). Bpdl is required for transcription from all pol III promoter types 
and in contrast to Brfl, Bdpl fonns a weak association with TBP when there is 
no DNA template present (Schramm et a l, 2000). As with Brfl, Bdpl makes 
direct contacts with TFIIIC, allowing TFIIIC to bring TFIIIB to the promoter 
(Geiduschek and Kassavetis, 2001). Recently, HsBdpl activity has been 
shown to be an essential component in TFIIIC 1 and TFIIIC 1-like activity when 
the addition of this protein alone was able to reconstitute transcription from a 
VAl gene (Weser et a l, 2004).
Brfl shares N-terminal homology to the pol II transcription factor IIB (TFIIB) 
(Schramm and Hernandez, 2002). Brfl is a 90kDa protein that is initially 
contacted by DNA-bound TFIIIC, which then serves to recruit the pol III 
subunit C34 (RPC39 in human) (Brun et a l, 1997). Brfl is the only TFIIIB 
subunit to make direct contacts with pol III itself, localizing pol III to the 
transcription start site and facilitating transcription initiation. Dividing Brfl in 
half and using these two components in an in vitro transcription system still
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reconstitutes active transcription to the same degree as non-divided Brfl 
(Kassavetis et a l, 1998).
1.5.2 Assembly of transcription machinery on type I promoters
1.5.2.1 Transcription factor IIIA (TFIIIA)
Transcription initiation at a type I promoter requires the gene-specific 
transcription factor III-A (TFIIIA), a 40kDa single polypeptide. TFIIIA acts as 
a platform, allowing TFIIIC to be recruited onto type I promoters, although the 
manner in which TFIIIA promotes TFIIIC binding is uncertain (Schramm and 
Hernandez, 2002). This protein consists of nine tandem zinc fingers, the N- 
terminal three fingers recognizing the C- block, the middle fingers the 
intermediate element, and the C-terminal three fingers contacting the A- block 
(Nolte et a l, 1998; White, 2001b). C- block binding contributes to 95% of the 
total binding affinity of full length TFIIIA (Clemens et a l, 1992). After 
TFIIIC is bound to TFIIIA, the basal transcription machinery proceeds in the 
same order as in a type II promoter, TFIIIC bringing TFIIIB, and hence pol III, 
to the site of transcription initiation.
1.5.3 Assembly of transcription machinery on type III 
promoters
The TFIIIB that is recruited does not contain Brfl as in type I and II promoters, 
but instead Bdpl, TBP and Brf2, a Brfl-related factor. TFIIIB does not require 
TFIIIA or TFIIIIC for recruitment, but binds to the TATA box and FSE by the 
TBP subunit of TFIIIB and SNAPc (snRNA activator protein complex) (Lagna
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et a l, 1994; Murphy et a l, 1992). Recognition of the special promoter 
structure type III is complex. SNAPc and Oct-1 are recruited to the upstream 
sequence elements and bind cooperatively to their spatially separated PSE and 
DSE (Geiduschek and Kassavetis, 2001; Schramm and Hernandez, 2002). The 
affinity of SNAPc to its PSE is dependent on the DNA- bound Oct-1 and 
protein-protein interactions between SNAPc and Oct-1 increase TFIIIB- 
SNAPc recruitment (Murphy et a l, 1992). Once stabilized, PSE occupancy is 
stimulated, pol III is recruited and transcription is initiated.
1.5.4 Elongation and termination
Once pol III has been recruited to a promoter it separates the DNA helix 
around the initiation site, forming a transcription bubble (Geiduschek and 
Kassavetis, 2001). This process may require the active participation of TFIIIB, 
possibly through promoter opening, but the exact mechanism remains to be 
determined (Constanzo et a l, 2001; Kassavetis et a l, 1998). As pol III 
transcribes the gene, the DNA bubble moves with it, elongating RNA at an 
average of -20 nucleotides per second. Transcription by pol III is not uniform, 
however, as pol III moves along certain nucleotides more quickly than others 
(White, 2001a). Studies have shown that pol III severs its connection with 
TFIIIB at an early stage, after several ribonucleotides have been synthesized 
(Geiduschek and Kassavetis, 2001). Pol III does not require elongation factors, 
unlike pol I and pol II. The small size of class III genes may not make this 
necessary, or it is possible that one or more pol III subunits may carry out this 
function (White, 2001b).
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Transcription termination begins when pol III recognizes short runs of U 
(Geiduschek and Kassavetis, 2001). The efficiency of termination seems to be 
influenced by the flanking sequence and increases with greater lengths of U- 
run. In human VAl and tRNA genes (as well as yeast class III genes), pol III 
is recycled without being released from the template and, hence, the slow 
initiation step is avoided. This mechanism may occur by specific handing-off 
mechanisms or purely stoichiometric recycling. In yeast, pol III has been 
shown to be directly transferred from the tennination site to the promoter. A 
preferential termination pathway allows RNA release and transcription 
reinitiation, without the release of pol III (Dieci and Sentenac, 1996). The 
precise mechanism exploited by human pol III still remains to be determined, 
but it has been shown to be retained in the original transcription complex on 
VAl and tRNA genes without dissociating after each transcriptional round and 
may be assisted by TFIIIB and TFIIIC (Ferrari et a l, 2004; White, 2001b).
1.6 Proteins influencing pol III transcription
Various proteins have been found to influence pol III transcription, mainly 
through targeting transcription factor IIIB, including c-Myc, retinoblastoma 
protein (RB), p53, and protein kinases CK2 and ERK.
1.6.1 Influencing pol III transcription during proliferation
1.6.1.1 c-Myc
Overexpression of the cellular oncogene product c-Myc has been studied in a 
variety of human cancers including lymphomas and leukaemias (Spencer and 
Groudine, 1991). c-Myc is able to coordinate cell division and growth through 
pol II and pol III and enhances pol I transcription of rRNA genes leading to
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increased protein biosynthesis (Grandori et a l, 2005). c-Myc directly binds to 
TFIIIB through a protein-protein interaction between TFIIIB and the N- 
terminal transactivation domain of c-Myc. The interaction between c-Myc and 
TFIIIB is significant, considering TFIIIB’s ability to regulate pol III 
transcription. Activation of c-Myc has been found to increase translation and 
growth, which precedes DNA replication and cell division (Rosenwald, 1996; 
Schmidt, 1999). Loss of endogenous c-Myc depleted from HeLa cells using 
small interfering RNA caused a decrease in pol III products, namely tRNA and 
5S rRNA (Felton-Edkins et a l, 2003b). Overabundance of exogenous c-Myc 
rapidly increases transcription of the latter two gene types (Gomez-Roman et 
a l, 2003). These experiments in combination provide evidence that c-Myc 
directly regulates pol III transcription via TFIIIB.
1.6.1.2 Retinoblastoma protein (RB)
The discovery of RB was pivotal to the further understanding of the 
mechanisms that influence a cell’s transformation. It has been suggested that 
the pathway involving RB may be disrupted in all human malignancies 
(Weinberg, 1995). RB contains regions of homology to both TBP and Brfl, 
which may assist in its ability to mimic these molecules and therefore disrupt 
TFIIIB (Larminie et a l, 1997). Using extracts prepared from RB-knockout 
mice, Larminie et a l, demonstrated a specific increase in TFIIIB activity when 
the Rb gene was disrupted, as well as a higher rate of pol III transcription 
(1997). RB is thought to decrease the rate of transcription by disrupting the 
interaction between TFIIIB and TFIIIC and also disturbing the interaction 
between TFIIIB and pol III (Sutcliffe et al., 2000). This, in turn, inhibits the 
synthesis of tRNA and 5S rRNA. In non-proliferating cells, RB is primarily
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found in its underphosphorylated form, interacting with many proteins, 
including TFIIIB (Scott et a l, 2001). TFIIIB only associates with this 
underphosphorylated form of RB. The TFIIIB-RB complex inhibits further 
binding of TFIIIB to TFIIIC, which decreases class III gene expression 
(Sutcliffe et a l , 2000). Loss of class III gene expression (namely rRNA and 
tRNA) leads to decreased protein biosynthesis and may constitute an important 
role in tumour suppression (White, 1998). RB and TFIIIB together play an 
important role in cell cycle progression, which will be discussed below.
Two closely RB-related proteins, pl07 and pI30, also appear to play a role in 
repression of TFIIIB. Sutcliffe et a l, demonstrated that a subunit of TFIIIB 
interacts physically with p i07 and p i30. This TFIIIB subunit was Brfl, 
demonstrated by binding of both endogenous and recombinant p i07 and p i30 
to Brfl during immunoprécipitation assays (Sutcliffe et a l, 1999). When p i07 
and pl30 are not repressing TFIIIB, pol III transcription is deregulated and 
transcription increases, with a consequent increase in the cell’s biosynthetic 
capacity (reviewed in White, 1997). In contrast, pol I transcripts only appear 
to increase in fibroblasts lacking RB and p i30, with no increase in fibroblasts 
lacking p i30 and p i07 (Ciarmatori et a l, 2001).
1.6.1.3 ERK
Protein kinases ERK and CK2 have been shown to stimulate pol III 
transcription in mammalian cells, via TFIIIB (Felton-Edkins et a l, 2003b; 
Johnston et a l, 2002). ERK is associated with the promotion of growth 
through activation of translational capacity and ribosome biogenesis 
(Brandenburger et a l, 2001 ; Whitmarsh and Davis, 2000). Felton-Edkins et al
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revealed that activation of ERK is required for TFIIIB binding to pol III and 
TFIIIC, and that only the activated form of ERK binds TFIIIB (2003). More 
specifically, the interaction between TFIIIB and ERK was found to be between 
ERK and the subunit of TFIIIB, Brfl, which is phosphorylated by ERK in vitro 
and in vivo, Co-immunoprecipitation assays using cells incubated with serum 
or MEK inhibitor suggests that ERK activity may promote the interaction of 
TFIIIB, TFIIIC2, and pol III in proliferating cells, perhaps stimulating 
initiation complex assembly. However, because phosphorylation of Brfl is 
only partially hindered by blocking ERK activity in vivo, another protein 
kinase, such as CK2, may be required for maximal transcription (Felton-Edkins 
et a l, 2003b; Johnston et a l, 2002).
1.6.2 Pol III transcription during cellular stress
1.6.2.1 CK2
CK2 has many roles within a cell. One role includes stimulation of pol III
transcription in yeast and mammalian cells, via TFIIIB, directly linking it with
cellular growth and proliferation (Brown et a l, 2000; Carroll and Marsjak,
1989; Felton-Edkins et a l, 2003b; Johnston et a l, 2002; Munstermann et a l,
1990). In another role involving cellular stress in yeast, CK2 relays DNA
damage signals to the pol III machinery, releasing its catalytic subunits while
the remaining subunits stay bound to TFIIIB. In turn, TFIIIB cannot be
phosphorylated, and hence, activated, which results in the repression of pol III
transcription (Ghavidel and Schultz, 2001). Johnston et a l, demonstrated the
association between CK2 and TFIIIB, and CK2’s ability to stimulate pol III
transcription by binding and phosphorylating TFIIIB and assisting its
recruitment by TFIIIC2, More specifically, Brfl was found to require
23
1 Introduction
phosphorylation by CK2 in order to interact efficiently with TFIIIC2. 
Transcription by pol III requires phosphorylation by CK2, however, CK2 
phosphorylation of Bdpl, Brf2 and TBP together is inhibitory (Hu et a l, 
2003).
1.6.2.2 p53
p53 is an important tumour suppressor that is inactivated in many human 
cancers (Vousden, 2000). p53 may become activated in response to cellular 
stress such as; hypoxia, radiation and oncogenic stimuli, inducing cell death. 
In most of these cancers the mutation lies in the central core domain, a region 
fundamental in its ability to regulate TFIIIB (Stein et a l, 2002). The tumour 
suppressor protein p53 targets TFIIIB, blocking its function and therefore 
serving as a general repressor of pol III transcription (Cairns and White, 1998). 
p53’s N-terminal domain binds TFIIIB, through its direct interaction with TBP, 
and thereby prevents promoter occupancy by TFIIIB (Chesnokov et a l, 1996; 
Crighton et a l, 2003), When this occurs, TFIIIB disassociates from both 
TFIIIC2 and pol III (Crighton et a l, 2003). TFIIIB appears to be less 
susceptible to p53 once it has assembled into a preinitiation complex. 
Immunoprécipitation assays have shown that Brfl can assemble into specific 
complexes with cellular p53 (Cairns and White, 1998). Since TFIIIB has an 
important role in a cell’s biosynthetic capacity, p53’s ability to release TFIIIB 
from repression may add to the loss of growth control in many types of 
tumours.
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1.6.2.3 Mafl
Mafl, a novel and conserved protein, has recently been found to negatively 
regulate pol III transcription in Saccharomyces cerevisiae (Pluta et a l, 2001). 
Pol III repression by Mafl occurs in response to a variety of conditions, 
suggesting that this protein may be a convergence point in major nutritional 
and stress-signalling pathways. This protein will be discussed further in the 
results section.
1.7 Regulation of pol III during the cell cycle
TFIIIB has been shown to be an important target for cell cycle regulation of 
pol III transcription. Through this factor, pol III transcription may be 
deregulated, providing striking evidence that deregulation tlirough TFIIIB 
plays an essential role in driving mammalian cells towards tumour 
development.
There are four phases of the somatic cell cycle; S phase (for DNA Synthesis), 
where chromosomal replication occurs, M phase (for Mitosis), and G1 and G2, 
or Gap phases. Two thirds of the way through G1 the restriction point (R) 
occurs, where the cell is committed to replicate and divide irrespective of the 
presence of external growth factors. The cell cycle has a profound effect upon 
gene expression, especially during mitosis, when transcription is generally 
repressed. TFIIIB subunits TBP and Brfl have been shown to be 
hyperphosphorylated during this period, which inactivates TFIIIB and 
represses pol III transcription (Fairley et a l, 2003; White et a l, 1995). As 
TFIIIB leaves mitosis, hyperphosphorylation of TFIIIB is rapidly reversed.
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TFIIIB activity remains low in early G1 phase and increases gradually as cells 
move into S phase (White et a l, 1995). Because of this increase, pol III 
transcription is 2 to 3- fold higher in S and G2 than in early Gl. During early 
Gl, active TFIIIB is a limiting factor for pol III transcription, but by S and G2 
phases it increases to levels over that of TFIIIC. This increases the rate of pol 
III transcription at this time point.
This was further demonstrated by Scott et al using serum-starved cells and 
add-back experiments, where fractions containing TFIIIB stimulated 
transcription in serum-starved and growing cells (2001). No response was 
observed when a fraction containing TFIIIC and pol III was added. This 
suggests that TFIIIB is indeed limiting, while TFIIIC and pol III are in excess. 
The subunits Brfl and TBP did not decrease during serum deprivation, 
suggesting that the amount of TFIIIB is not responsible for its own loss of 
activity.
RB has proved to be an important factor in cell cycle regulation in its 
interaction with TFIIIB. RB and RB-related protein p i30 bind and repress 
TFIIIB during GO and early Gl phase, then dissociate from TFIIIB shortly 
before S phase, causing an increase in transcription (Brown et a l, 2000). RB 
and p i30 were shown to bind to the Brfl subunit of TFIIIB (Scott et a l, 2001). 
This dissociation is caused by the phosphorylation of RB in mid- to late Gl 
phase. Because TFIIIB is known to bind only the underphosphorylated form 
of RB, it suggests that TFIIIB is released from repression by RB at the Gl/S 
transition due to hyperphosphorylation of RB by the cyclin-dependent kinases 
D and E.
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TFIIIB and its ability to regulate pol III transcription in growth-arrested cells 
has been the source of conflicting experiments. Tower and Sollner-Webb 
concluded that a specific reduction in TFIIIB activity was responsible for down 
-regulating pol III transcription in growth-arrested ceils; however, it was not 
determined by what mechanism (1988). Another laboratory demonstrated that 
HeLa cells down-regulate pol III transcription when grown in low serum, due 
to a decrease in the activity of TFIIIC2 (Hoeffler et al, 1988). However, HeLa 
cells grow actively in these studies, despite low serum conditions, so these 
experiments may not provide a clear picture of the actions of pol III as it exits 
the cell cycle.
1.8 Cell growth and cell cycle progression
Although cell growth is necessary for sustaining eukaryotic organisms, the
mechanisms in which cell growth and cell cycle progression are coupled
together remains fairly elusive. Cell growth is necessary for cell cycle
progression, while cell cycle progression is not required for cell growth
(Johnston et a l, 1977). Further insight was achieved when studies showed that
cells must reach a critical mass before DNA replication and cell division occur
(Fingar et a l, 2002; Johnston et a l, 1977; Zetterberg and Killander, 1965).
This critical mass is the accumulation of protein that makes up 80 to 90% of a
cell’s dry mass (Zetterberg and Killander, 1965). The amount of critical mass
becomes important when linked to a cell’s biosynthetic capacity and how it is
controlled. In transformed and tumour cells, the pathways that control the
accumulation of mass and, hence, progression into the cell cycle is altered,
causing abnormal and uncontrolled cell division. Investigation into the
27
1 Introduction
common proteins and pathways that link cell cycle progression and cell growth 
may allow further insight into the events that must take place for cell 
transformation.
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1.9 Aims of Masters Thesis
TFIIIB has proved to be an essential molecule involved in pol III basal 
machinery and regulation and is an important target for cell cycle regulation in 
actively proliferating cells (White, 1998). TFIIIB is an important determinant 
of 5S rRNA and tRNA production, affecting a cell’s biosynthetic capacity. 
The importance of this transcription factor was further proven when many key 
proteins such as tumour suppressors p53 and RB, oncogene c-Myc, kinases 
CK2 and ERK, and negative pol III regulator Mafl were found to target this 
molecule. The mechanisms in which these proteins affect TFIIIB have been 
researched, hut the exact molecular mechanisms of regulation are not yet 
understood. This is vital when considering that the deregulation of TFIIIB 
may be a significant step towards tumour development.
My overall project aims were to use three different methods to decrease pol III 
transcription, and observe transcript expression, proteins levels, and 
proliferation rates. Brfl was found to be an important TFIIIB subunit affected 
by all of the key proteins listed above, therefore, this subunit seemed most 
likely to have an effect on transcription, and hence, proliferation rates, when 
targeted by small interfering RNA (siRNA) in mammalian cells (Crighton and 
Woiwode; Desai et a l, 2005; Felton-Edkins et a l, 2003b; Gomez-Roman et 
a l, 2003; Johnston et a l, 2002; Larminie et a l, 1997).
Although siRNA teclinology can be extremely effective, it can be time-
consuming and expensive, so other methods were sought to decrease pol III
transcription. In vitro, tagetitoxin has been found to specifically inhibit pol III
transcription, probably by inhibiting elongation and delaying the accumulation
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of full-length transcript (Steinberg and Burgess, 1992; Steinberg et a l, 1990). 
Tagetitoxin seemed an excellent candidate for decreasing pol III transcription 
in mammalian cells, and may prove to be a more straightforward method, 
bypassing complications such as siRNA design and transfection efficiencies.
Yet another way to decrease pol III transcription is to use a negative effector of 
RNA polymerase III, such as M afl. In Saccharomyces cerevisiae, Mafl was 
found to be a nuclear protein that interacts with pol III and serves to help 
regulate the level of cellular tRNA in response to external signals (Pluta et a l , 
2001). The last aim of this project was to create a Tet-On mammalian cell line 
that overexpresses Mafl when induced, to observe the levels of pol III 
transcripts and proliferation rates. Mafl siRNA was also used to examine 
opposing effects.
Thus, the main objective of this Masters is to gain insight into the effects of 
decreasing pol III transcription by various methods in mammalian cell lines, 
targeting either the polymerase itself, or proteins that interact with it.
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Materials and Methods
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2.0 Materials and Methods
2.1 Cell culture
2.1.1 Culture of HeLa, NIH 3T3, and MCF-7 cells
HeLa and NIH 3T3 cells were cultured in DMEM (Dulbecco’s Modified Eagle 
Medium), supplemented with 10% (v/v) foetal bovine serum (FBS), 2 nM L- 
glutamine, 100 U/ml penicillin and 100 pg/ml streptomycin. MCF-7 cells were 
grown in RPMI 1640 medium, supplemented with 10% FBS, 2 nM L- 
glutamine, 100 U/ml penicillin and 100 pg/ml streptomycin. All cell types 
were grown in a humidified atmosphere which contained 5% CO2  at 37°C. A 
class II hood was used for aseptic techniques, along with sterile equipment and 
reagents. Cells were passaged when subconfluent; approximately every 2 to 3 
days. After media was aspirated from the flask, 2 ml of buffered trypsin- 
EDTA (0.05% (w/v) trypsin, 0.02% (w/v) EDTA) was added to the cells, and 
then aspirated immediately. A further 2 ml was added and left at room 
temperature (~22°C) until cells appeared to begin to dislodge from the flask 
wall, approximately 1 -4 minutes, depending on the cell type. The remaining 
trypsin was then aspirated. The flask was gently tapped and fresh media was 
immediately added to the dissociated cells in order to neutralise the trypsin.
Cryo-freezing was used for storage of all cell lines. Cells were trypsinized as 
described above and, following pelleting by centrifugation, cells were 
resuspended in a solution of 70% FBS, 20% DMEM and 10% 
dimethylsulphoxide (DMSO) with no other supplements. Cells were aliquotted 
into cryo-tubes at density of 2x10^ cells/ml/tube and frozen in stages by 
initially being placed at -80°C overnight and subsequently being transferred to 
liquid nitrogen storage the next day. Thawing of cells was performed rapidly
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by placing cryo-tubes in a 37°C water bath until just thawed. Cells were then 
mixed with fresh media, centrifuged, and the supernatant aspirated off to 
ensure removal of DMSO prior to resuspension in normal culture media, 
containing 10% (v/v) FBS DMEM.
2.1.2 Culture of pTRE2.HA.HsMafl (Tet-on) HeLa cells
HeLa cells that express the tetracycline-controlled transactivator (tTA) were 
purchased from Clontech, BD Biosciences and routinely cultured in DMEM 
supplemented with 10% FBS (Tet-System Approved, Clonetech), 2 mM L- 
glutamine, 100 U/ml penicillin, 100 pg/ml streptomycin, 100 pg/ml G418 and 
100 pg/ml hygromycin B. All other culturing techniques were performed as in 
2.1.1, above.
2.2 Preparation of total cellular RNA
Total cellular RNA was isolated from cells when approximately 80% confluent 
using TRI reagent (Sigma), a solution of guanidine thiocyanate and phenol, in 
accordance with the manufacturer’s instructions. Media was aspirated off cells 
grown in 10 cm tissue culture dishes and residual media removed with two 
washes using 5 ml of ice-cold PBS. Cells from each dish were harvested by 
scraping in 1 ml of TRI reagent per dish and transferred to a sterile eppendorf 
tube. Cells were left to stand for 5 minutes at room temperature to ensure 
complete dissociation of nucleoprotein complexes. 0.2 ml of chloroform was 
then added to each tube and the samples vortexed for 15 seconds. The samples 
were then allowed to stand for a further 15 minutes at room temperature prior 
to being centrifuged at 13,000g for 15 minutes at 4°C. This resulted in 
separation of the samples into three phases: a lower red organic phase
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containing protein, a middle white interphase containing precipitated DNA and 
an upper colourless aqueous phase which contains the RNA. The upper phase 
was carefully removed by pipetting, ensuring no contamination from the 
remaining phases, and transferred to fresh eppendorf tubes. Isopropanol (500 
pi) was added to each of these tubes containing the aqueous RNA and 
thoroughly mixed by repeated inverting. Following 5-10 minutes incubation 
at room temperature to allow maximal precipitation of RNA, samples were 
centrifuged at 13,000g for 10 minutes at 4°C. The supernatant was then 
removed and the remaining RNA pellet was washed with 1 ml of 75% (v/v) 
ethanol made up with diethypyrocarbonate (DEPC)-treated dHzO. DEPC is 
0 .1 % (v/v) diethypyrocarbonate/sterile water which is mixed into solution, left 
overnight at room temperature and then autoclaved to inactivate the remaining 
DEPC. The samples were then vortexed briefly, subsequently 
microcentrifuged at 7,500g for 5 minutes at 4°C and the supernatant aspirated 
off. Residual supernatant was removed with a P20 pipette following pulse 
microcentrifugation. Appropriate volumes of DEPC-dHzO, in the range of 10- 
30 pi (depending on the size of the RNA pellet), were added to the RNA 
pellets and the samples were heated in a 65 °C water bath for 10 -  15 minutes 
to facilitate resuspension of the RNA. The samples were stored at -80°C.
2.3 Quantification of nucleic acids
Concentrations of nucleic acids were determined by spectrophotometry, where 
an OD of 1 at 260 nm correlates to 50 pg/ml of double-stranded DNA and 40 
pg/ml of single-stranded DNA and RNA. Readings were zeroed in the same 
solution in which the sample was diluted. RNA concentration was determined 
by A2 6 0 using the calculation:
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RNA concentration (pg/ml) = absorbance at 260 nm x 40 x dilution factor.
DNA concentration was determined by the equation:
DNA concentration (pg/ml) = absorbance at 260 mn x 50 x dilution factor.
A ratio of absorbance at 260 nm to 280 nm in the range of 1.8 to 2 indicated 
the RNA samples were relatively free from contamination with protein.
2.4 Reverse transcriptase-polymerase chain reaction 
(RT-PCR)
2.4.1 cDNA preparation
cDNAs were prepared from 3 pg of RNA (diluted to 1 pg/pl). 2 pi of random 
primers (hexanucleotide mix, (Roche)) diluted 1:10 with DEPC- dHaO) was 
mixed with 19 pi of DEPC-dHaO. Primer annealing was carried out at 80“C in 
a final volume of 24 pi and allowed to proceed for 10 minutes before 
transferral to ice, then microfuged briefly. 8  pi of 5 x First Strand Buffer 
(Invitrogen), 4 pi of 0.1 M dithiothreitol (DTT), 2 pi of 10 mM dNTP mix 
prepared in DEPC-dHaO) and 1 pi (200U) of Superscript II Reverse 
Transcriptase (Invitrogen) was added to initiate reverse transcription, which 
was performed for 1 hour at 37°C before the reaction was stopped by heating at 
70°C for 15 minutes. Resulting cDNA was stored at -20°C.
2.4.2 Polymerase chain reaction
PCRs were carried out using a Techne TC-312 PCR thermocycler. 2 pi of 
cDNA was amplified with 20 pml of the relevant primers under gene-specific 
denature, cycling and final extension cycling parameters (Table 2.1, below). In 
addition to the primers, reaction mixtures also contained 0.5 U of Taq
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polymerase (Promega), 1 X Taq DNA polymerase buffer (Promega), 1.5 mM 
MgCla, 0.2 mM of each dNTP and 1 pCi of [a^^P] dCTP (Amersham) made up 
with nuclease-free water to 2 0  pi final volume.
Table 2.1 Primers employed in RT-PCR reactions
Transcript Primers Product
Size
Cycle
Number
Program
Parameters
ARPP PO
5 ’-GCACTGGAAGTCCAACT 
ACTTC-3’
5 ’-TGAGGTCCTCCTTGGT 
G A AC AC-3’
265bp 18-22
95°C for 2 min 
95°C for 1 min 
58°Cfor30 s 
72°C for 1 min 
72°C for 3 min
B2
5 ’-GGGGCTGGAG AGATGG 
CT-3’
5’-CCATGTGGTTGCTGGG
AT-3’
120bp
15-18
95°C for 3 min 
95°C for 30 s 
58°Cfor30s 
72°C for 30 s 
72°C for 5 min
Brfl
5 ’-AAATTCTGTGAGCCTCT 
TCCGTAGTG-3’
5 ’ - AG ACCC ATGCTTGTAC A 
TTCCACG-3’
260bp 21-24
95 °C for 2 min 
95°C for 1 min 
60°C for 1 min 
72°C for 1 min 
72 °C for 5 min
Lamin A/C
5 ’-GCTGAAAGCGCGCA 
ATAC
5 ’ -C AGTCGGGTCTC ATG 
ACG-3’
333bp 30-35
94°C for 3 min 
94°Cfor30 s 
56° C for 30 s 
72°Cfor30 s 
72° for 4 min
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Mafl (mouse)
5’-GCAGTTCTGCCAGG
AGGGCCA-3’
5 ’ -CTCC ATGGTGCTGGTCTC 
CTC-3’
613bp 25-30
95°C for 2 min 
95°C for 30 s 
60°C for 30 s 
72°C for 1 min 
72°C for 5 min
Mafl (human)
5 ’ -CC ATG A ACTC AC AGCTG 
AC-3’
5 ’ -GGCTCTGCTG A AGTC AT 
AG-3’
307bp 25-30
95°C for 2 min 
95°Cfor30 s 
58°C for 30 s 
72°C for 1 min 
72°C for 5 min
5 ’ -GGCTCTGTGGCGC A ATG 
GATA-3’
5’-TTCGAACCCACAACCTT
TGAATTGCTC-3’
74bp 20-22
95° for 2 min 
95° for 30 8 
66° for 30 s 
72° for 15 s 
72° for 5 min
tRNA^'"
5 ’-GTC AGGATGGCCGAG 
TGGTGTAAGGCGCC-3 ’ 
5’CCACGCCTCCATACGGAG 
ACCAGACCC-3’
88bp 25-30
95°C for 3 min 
95°C for 30 s 
68°C for 30 s 
72°C for 30 s 
72°C for 5 min
tRNA^""
5 ’-GG ATGATCCTC AGTG 
GTC-3’
5’-GGTGGAATTGAACCA
CTC-3’
74bp 21-24
95°C for 3 min 
95°C for 30 s 
60°C for 30 s 
72°C for 30 s 
72°C for 5 min
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5S rRNA
5’-GGCATACCACCCTGAA
CGC-3’
5’-CAGCACCCGGTATTCCC
AGG-3’
107bp 19-22
95 °C for 3 min 
95° for 30 s 
58° for 1 min 
72° for 1 min 
72° for 10 min
7SK
5 ’ -CG ATCTGGTTGCG AC AT 
CTG-3’
5 ’-CGTTCTCCTACAAATG 
G AC-3’
247bp 25-30
95°C for 3 min 
95°C for 30 s 
57°C for 30 s 
72°Cfor30s 
72°C for 10 min
snRNA U6
5 ’-GCTCGCTTCGGCAGC A 
CATATAC-3’
5’-TATCGAACGCTTCACGA
ATTTGCG-3’
96bp 18-20
95°C for 3 min 
95°C for 1 min 
60°C for 30 s 
72°C for 1 min 
72°C for 5 min
Reaction products were resolved on 7% (v/v) polyacrylamide sequencing gels 
containing 7 M urea and 0.5 x TBE (45 mM Tris-HCl, 45 mM boric acid, 
0.625 mM EDTA pH 8.0). Gels were pre-run for 30 minutes at 40 W in 0.5 x 
TBE and 1.5 pi of each sample was loaded after being boiled at 100°C for 2 
minutes. Electrophoresis was carried out for a further 1 hour at 40 W and the 
gel subsequently vacuum-dried at 80°C for 1 hour before being exposed to 
autoradiography film in order to detect the radiolabelled products.
2.5 Preparation of whole cell extracts
All whole cell extracts were prepared from cells grown in 6 -well culture plates 
or 1 0  cm tissue cultme dishes to facilitate scraping, and were harvested at 
approximately 80% confluency. Preparation was performed on ice as rapidly
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as possible and all solutions and tubes were kept ice-cold to maintain cell 
activity. Cells were washed twice with 5 ml of PBS before being scraped with 
a plastic spatula into 5 ml of ice-cold PBS. Cells were collected in chilled 50 
ml Falcon tubes and pelleted by slow centrifugation at llOOg for 8  minutes at 
4°C. A small volume of fresh ice-cold PBS was used to resuspend the cell 
pellets and allow the cells to be transferred to eppendorf tubes. These were 
then microcentrifuged briefly at 4°C to re-pellet the cells and the PBS 
removed. The volumes of cell pellets were then measured by comparison with 
pre-measured volumes of water. Optimal micro extraction requires pellets to be 
between 50-150 pi, giving approximately 0.5-3 x 10^  cells; larger pellets were 
subdivided. An equal volume of freshly made pre-cooled microextraction 
buffer (450 mM NaCl, 50 mM NaF, 20 mM Hepes pH 7.8, 25% glycerol, 1 
mM DTT, 0.5 mM PMSF, 0.2 mM EDTA, 40 pg/ml bestatin, 1 pg/ml trypsin 
inhibitor, 0.7 pg/ml pepstatin, 0.5 pg/ml aprotinin, 0.5 pg/ml leupeptin) was 
added to the cells and, following resuspension, the cells were immediately 
snap-frozen on dry ice. Cells were then placed in a 30°C water bath until just 
thawed before being immediately returned to diy-ice. This freeze-thaw 
procedure was performed a total of 3 times to ensure optimal cell lysis, with 
cells then being microcentrifuged at 7,000g for 7 minutes at 4°C after the third 
thaw. The supernatant was carefully decanted into a fresh tube, leaving behind 
the cell debris, and then promptly aliquotted and snap frozen. These extracts 
were then stored at -80°C.
2.6 Measuring protein concentration
The concentration of proteins in whole cell extracts was determined by using 
Bradford’s reagent (Biorad). Quantification of the colour reaction produced
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when 1 ml of diluted reagent (1:4 in distilled water) was mixed with a volume 
of sample containing protein in the range o f- 1 - 1 2  pg gave a precise indication 
of protein concentration. A Bradford assay standard curve was made by 
measuring the absorbance of bovine serum albumin (BSA) standards at 595 nm 
in a UV spectrophotometer, as increasing amounts of protein in Bradford’s 
reagent creates a linear curve. Once a standard curve was created within 
Microsoft E x c e l ™ ,  sample measurements of absorbance were plugged into the 
equation created by the standard curve, in this way obtaining the protein 
concentration. Three dilutions of each sample were measured and averaged to 
provide accurate concentrations.
2.7 SDS-polyacrylamide gel electrophoresis (PAGE) 
analysis
2.7.1 Separation of proteins by SDS-PAGE
Proteins were resolved on denaturing polyacrylamide gels according to 
molecular weight by electrophoresis. Typically, 7.8% polyacrylamide 
resolving mini-gels (375 mM Tris pH 8 .8 , 0.1% SDS) were used with a 
stacking layer comprised of 4% polyacrylamide gel (125 mM Tris pH 6 .8 , 
0,1% SDS) based on the discontinuous buffer system described by Laemmli 
(Laemmli, 1970). Samples were boiled for 2 minutes in 1 x protein sample 
buffer (62.5 mM Tris pH 6 .8 , 0.5% SDS, 5% |3-mercaptoethanol, 10% 
glycerol, 0.125% bromophenol blue) prior to loading. Electrophoresis was 
performed in 1 x SDS running buffer (0.1% SDS, 76.8 mM glycine, 10 mM 
Tris, pH 8.3) at an initial voltage of 100 V while the bromophenol dye front 
moved through the stacking gel and a subsequent voltage of 150 V after
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reaching the resolving gel. Electrophoresis was allowed to proceed until the 
dye front had reached the bottom of the gel, approximately 1 -1 .5  hours.
2.7.2 Western blotting
Electrophoretic transfer of proteins resolved by SDS-PAGE to PVDF 
membrane was achieved using the BioRad Mini Trans-Blot Electrophoretic 
Transfer Cell system. Transfer was carried out in 1 x transfer buffer (76.8 
mM glycine, 10 niM Tris, pH 8.3, 16.5% methanol) at 50 V for 1 hour. 
Transfer sandwich was placed in the transfer gel tank alongside an ice pack, or 
was performed at 4°C. Following transfer, the membrane was blocked in milk 
buffer (32.5 mM Tris, 150 mM NaCl, 0.2% Tween-20, 4% skimmed milk 
powder (Marvel)), for 1 hour at room temperature. Membranes were incubated 
with primary antibodies (typically a 1 : 1 0 0 0  dilution in milk buffer) overnight 
at 4°C, or for 2 hours at room temperature (-22°C). Excess primary antibody 
was removed by washing the blot 3 times for 2 minutes in fresh milk buffer 
before incubating for 1 hour at room temperature with the appropriate 
horseradish peroxidase-conjugated secondary antibody ( 1 : 1 0 0 0  dilution in milk 
buffer) (DAKO). To ensure removal of excess secondary antibody, the blot 
was sequentially washed in batches of fresh milk buffer, 3 times for 2 minutes, 
followed by 2 washes for 15 minutes. After one further 5 minute wash using 1 
X TBS (2.5 mM Tris-HCl pH 7.6, 15 mM NaCl), the blot was developed using 
the enhanced chemiluminescence method (ECL'^^, Amersham) as directed by 
the manufacturer.
2.7.3 Western signal detection
Horse radish peroxidase-conjugated secondary antibodies were used to detect 
signals on Western blots. Chemiluminescence detection (using ECL”^^,
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above), was performed by adding a ratio of 1 part reagent 1 to 1 part reagent 2  
to the filter. The solution was applied to the filter for 1 minute at room 
temperature. The solution was then gently wiped away with blotting paper, 
covered in cling film, exposed to ECL film (Amersham Pharmacia) for varying 
lengths of time, and then developed using the X-OMAT film processor.
2.7.4 Primary antibodies
Table 2.2
Protein Antibody Type Company
Actin C ll Polyclonal Santa Cruz Biotechnology
Brfl SK-2839 Polyclonal In house
Mafl 1167 Polyclonal In house
Spl 420 Monoclonal Santa Cruz Biotechnology
2.8 Transformations
2.8.1 Storage of competent cells
1 ml of bacterial culture was added to 40% (v/v) glycerol solution (in sterile 
distilled water), before freezing in liquid nitrogen.
2.8.2 Transformation of competent cells
E.coli XL-1 Blue supercompetent cells (Stratagene) were transformed for 
plasmid storage and propagation. Cells, stored at -80°C and highly 
temperature sensitive, were thawed on ice to prevent loss of transformation
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ability. 0.4 jllI  of (3-mercaptoethanol, which enhances transformation 
efficiency, was added to the 50 pi of cells that were required per 
transformation reaction to give a final concentration of 25 mM. Typically 10 -  
20 ng of plasmid DNA was then gently mixed into the chilled cells. The 
contents were gently tapped occasionally during a 30 minute incubation on ice, 
before being heat shocked at 42°C for exactly 45 seconds and then transferred 
to ice for a further 2 minutes. Cells were incubated at 37°C for 1 hour on an 
orbital shaker (225 -  250 rpm) following the addition of 450 pi of preheated 
(42°C) SOC medium (LB broth, 0.04% (w/v) glucose, 10 mM MgS0 4 , 10 mM 
MgCL). Typically 1 0 0  pi and 250 pi of the transformation mixture was then 
plated on LB agar (2% (w/v) LB, 2% (w/v) agar) plates containing 50 pg/ml 
ampicillin (Amp) and the plates were incubated at 37°C overnight to allow 
growth and colony-formation of the transformed cells.
2.9 Techniques used in the creation of the plasmid 
pTRE2.hyg.Ha.HsMafl
2.9.1 Preparation of plasmid DNA
For large scale plasmid DNA preparation, a single isolated bacterial colony 
was selected from a freshly-streaked plate and used to inoculate 5ml of LB 
medium containing the selective antibiotic (100 pg/ml ampicillin). This was 
allowed to incubate with vigorous shaking at 37°C for ~7 hours to form a mini­
culture and was subsequently used to inoculate 250 ml of LB medium 
containing 100 pg/ml ampicillin. Following an overnight incubation at 37°C 
on an orbital shaker (-300 rpm), cells were harvested by centrifugation at
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6,000g for 15 minutes at 4°C and plasmid DNA retrieved using the Qiagen 
Plasmid Maxi Kit.
The bacterial pellet was resuspended in 10 ml of Buffer PI (50 mM Tris-HCl 
pH 8.0, 10 mM EDTA, 100 pg/ml RNase A) and then gently, but thoroughly 
mixed with 10 ml of Buffer P2 (200 mM NaOH, 1% (w/v) SDS) to initiate an 
alkaline lysis reaction. This reaction was allowed to proceed for 5 minutes at 
room temperature before neutralising the lysate by the addition of 1 0 ml of 
chilled Buffer P3 (3 M potassium acetate, pH 5.5), which subsequently resulted 
in formation of a precipitate of potassium dodecyl sulphate. The SDS- 
denatured proteins and chromosomal DNA were co-precipitated with the 
detergent, whilst the plasmid DNA remained in solution due to a lack of close 
protein associations. Precipitation was enhanced by a 20 minute incubation on 
ice and the precipitate pelleted by centrifugation at 20,000g for 30 minutes at 
4°C. The supernatant containing plasmid DNA was promptly removed and 
applied to a Qiagen-tip 500 column, pre-equilibrated with 10 ml of Buffer 
QBT (750 mM NaCl, 50 mM MOPS pH 7.0, 15% (v/v) isopropanol, 0.15% 
(v/v) Triton X-100). Gravity flow allowed the supernatant to pass through the 
anion-exchange resin to which plasmid DNA is able to bind tightly. The resin 
was then washed twice with 30 ml of Buffer QC (1 M NaCl, 50 mM MOPS pH 
7.0, 15% (v/v) isopropanol) and the purified plasmid DNA was subsequently 
eluted with 15 ml of Buffer QF (1.25 M NaCl, 50 mM Tris-HCl pH 8.5, 15% 
(v/v) isopropanol) and precipitated with 10.5 ml of room-temperature 
isopropanol. This was immediately followed with a 15,000g centrifugation at 
4°C for 30 minutes. The plasmid DNA pellet was then washed with 70% (v/v) 
ethanol, dried at room-temperature for 5 -  10 minutes and resuspended in an
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appropriate volume of sterile water. The DNA was then quantified using the 
spectrophotometer, as in section 2.3.
2.9.2 Restriction digests
Restriction digests were performed in 20 pi volume and contained; 1 pg DNA, 
1 pi enzyme (or 1 pi each, if using two enzymes), 2  pi enzyme buffer 
(appropriate to the restriction enzyme being used), and were made up to the 
final volume with sterile distilled water. All enzymes and buffers were 
supplied by Promega. DNAs were digested with enzymes for 2 hours at 37°C. 
Amounts of DNA in a restriction digest varied between 1-3 pg for plasmid 
DNA and 3 - 5 pg for genomic DNA.
Digests were mixed with 6  x Agarose Gel DNA Loading Buffer (0.25% (w/v) 
Bromophenol Blue, 0.25% (w/v) Xylene Cyanol, 30% (v/v) glycerol),
analysed on 1% (w/v) agarose gels containing ethidium bromide (Sigma) and 
visualised on an ultraviolet light box. The concentrations of nucleic acid 
solutions were determined spectrophotometrically using a quartz cuvette,
2.9.3 Agarose gel electrophoresis of DNA
DNAs were separated in 1 % (w/v) agarose in Ix TAB (40 mM Tris-acetate, 1 
mM EDTA pH 8.0) containing 0.1 pg/ml ethidium bromide, using Ix TAB as 
the electrophoresis buffer. Sizes were compared to a 1 kb ladder (Gibco-BRL). 
Prior to loading, 6  x loading dye (0.25% (w/v) bromophenol blue, 0.25% (w/v) 
xylene cyanol, 30% (v/v) glycerol in water) was added to the samples to a final 
Ix concentration of loading dye in the sample.
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2.9.4 Purification of DNA from gels
DNA bands were excised from the gel using a sterile scalpel blade under a UV 
light, and the DNA extracted using the Qiagen Gel Extraction Kit according to 
the manufacturer’s instructions. DNA was typically eluted in 30 pi of pre­
warmed buffer EB (Qiagen) or H2 O.
2.9.5 DNA ligations
For cloning inserts into vectors, plasmid DNA containing the vector and the 
insert were digested with appropriate restriction enzymes, as described in 
sections 2.9.2 and 2.9.6. For directional cloning of inserts, two different 
enzymes were used to restrict the vector and the insert, which permits cloning 
of the insert into the vector in a predicted and directional manner. After the 
restriction digest, both vector and insert were electrophoresed on a 1 % (w/v) 
agarose gel and the DNA bands excised from the gel and gel-purified (see 
section 2.9.4).
For the ligation reaction, molecular ratios of 1:1, 3:1, and 6:1 (insert:vector) 
were used and typically 50-100 ng of vector. Ligation reactions were carried 
out with 2 pi 1 Ox T4 ligase buffer (Gibco BRL), with 1 pi (1 U) of T4 ligase 
(Gibco BRL) in a final volume of 20 pi with sterile water. The ligation was 
carried out overnight at 14°C. For transformation of XL 1-Blue, 5 pi of the 
ligase reaction was used.
2.9.6 Subcloning of M afl into pCDNA3.HA
In order to apply an HA- tag to Mafl, Mafl was first subcloned into the 
pCDNA3.HA vector, then digested out. The plasmid, pGEM-T.HsMafl was a
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gift from Olivier Lefebvre (CEA/Saclay, France). This plasmid was digested 
with BamYil and Sail. PCRs were then performed to insert a BamRl site onto 
the 5’ end of the gene (5’-GTAGCTGGATCCATGAAGCTATTGGA-3’ and 
5’-GGCGGCTCTAGAACGCGTCGACTCAAATAC-3’). The PCR product 
was then ran out on an agarose DNA gel, and the correct band excised. The 
excised product was then purified using the Qiagen Gel Extraction Kit. 
pCDNA3.HA and the HsMafl vector were then digested with BamRl and 
Xbal. The separate bands were cut from an agarose DNA gel and the products 
purified, as above. pCDNA3.HA and HsMafl were then ligated together. 
After ligation, E.coli XL-1 Blue supercompetent cells (Stratagene) were 
transformed with the ligated pCDNA3 .HA.HsMaf 1. In order to produce a high 
plasmid yield, cells were cultured in 5 mis (mini prep), then 250 mis (maxi 
prep). The presence of the plasmid was checked by digestion in both mini and 
maxi prep stages. PCR was then performed to add an Nhel site onto the 5’ end 
of the gene (5 ’-GCACGCGCTAGCATGGAATTCT-3 ’and 5’- 
GTAGCTGGATCCATGAAG CTATTGGAGAAC-3’). The PCR product 
was then run on an agarose DNA gel and the proper band excised and purified. 
This procedure produced HA.HsMafl.
2.9,7 Subcloning of HA.HsMafl into pTRE2.hyg
HA.HsMafl was digested with Nhel and pTRE2.hyg with Nhel and Sail. A
PCR cleanup was performed using the QIAquick PCR Purification Kit
(Qiagen), as per the manufacturer’s instructions. HA.Mafl was then ligated
into pTRE2.hyg, to create pTRE2.hyg.HA.HsMafl. Using the same competent
cells as above, transformations were done with ligated plasmid. As above,
mini, and then maxi preps were cultured to increase DNA yields of the
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plasmid. At each culture volume the plasmid was checked by digestion with 
Nhel and Sail enzymes. The final plasmid, pTRE2.hyg.HA.Hs.Mafl was sent 
for sequencing and yielded - 6 . 1  kb plasmid.
2.9.8 Stable transfection
HeLa-derived Tet-On cells for stable transfection were plated out at 2 x 10^  
cells/10 cm dish 24 hours prior to transfection, resulting in a confluency of -70 
-  80% at the time of transfection. Two 10 cm dishes were transfected with 5 
pg of pTRE2.HA.Mafl.hyg construct and 5 pg of the empty, pTRE2.hyg 
vector. Mastermixes for each set of 10 cm dishes were made up comprising 
the appropriate plasmid DNA and Opti-MEM I reduced serum medium (Gibco 
BRL) to give a volume of 100 pi per dish. Then, for each transfection, 25 pi of 
Lipofectamine reagent was diluted into 100 pi of serum-free medium. The two 
solutions were combined, mixed gently and incubated at room temperature for 
45 minutes in the dark to allow DNA-liposome complexes to form. While 
complexes were forming, cells were washed once with 3 mis of serum-free 
medium. For each transfection, 0.8 ml of serum-free medium was added to the 
tube containing the complexes. This was mixed gently and the diluted 
complex solution overlayed onto the rinsed cells. Cells were incubated with 
the complexes for 3 hours at 37°C in a CO2 incubator. Following incubation, 
10 mis of normal growth medium, plus G418 100 pg/ml, was added to each 
dish. Cells were allowed to grow for a further 24 hours before adding the 
selection agent hygromycin B (Melford Laboratories), at a concentration of 
600 pg/ml, to the culture medium. To ensure Tet-On gene expression system 
remained ‘switched off during the selection process, cells were cultured with 
Tet-approved FBS (BD Biosciences, Clonetech). Fresh complete selection
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medium, containing hygromycin, was replaced every four days. After about 
four days, cells began to die but were split if they reached confluency before 
massive cell death began. After two to four weeks, healthy hygromycin- 
resistant colonies were isolated and transferred to individual plates or wells. 
Potential clones were then screened using Mafl specific assays to identify the 
clones with the lowest background of Mafl gene expression and highest 
induction of Mafl gene expression. This was achieved by western blot using 
antibodies to both transfected Mafl (with the HA tag), and total Mafl, as well 
as RT-PCRs for Mafl.
2.10 Electroporation of HeLa and MCF-7 cells
For all electroporation experiments, an Amaxa Nucleofector (Amaxa GmbH) 
was used. HeLa cells were electroporated using the Cell Line Nucleofector'*'"^ 
Kit R (program 1-20), while MCF-7 cells were electroporated using the Cell 
Line Nucleofector™ Kit V (program P-20) following the procedures listed in 
the manufacturer’s instructions.
All siRNAs were designed and synthesised by Qiagen.
Lamin A/C [sense: r(CUGGACUUCCAGAAGAACA)dTdT; antisense: 
r(UGUUCUUCUGGAAGUCCAG)dTdT]
Brfl siRNA-1 [sense: r(GGAUGCAAUUGAGAUUGAA)dTdT; antisense: 
r(UUCAAUCUCAAUUGCAUCC)dTdG]
Brfl siRNA-2 [sense: r(GGAGG AGGUU G A AGGU G A A)dT dT ; antisense: 
r(UUCACCUUCAACCUCCUCC)dAdG]
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2.10.1 Electroporation of HeLa ceils in Brfl and Mafl siRNA 
experiments
HeLa cells were grown to -80% confluency before being used for 
electroporation. Cells were removed from flasks via trypinization (as above), 
and centrifuged at 1,1 OOg to produce a cell pellet. This pellet was resuspended 
in a specific volume of fresh media and cells were counted with a 
haemocytometer (Sigma). 1X10^ cells were used per nucleofection cuvette. 
The manufacturer’s instructions for nucleofection were followed, utilizing the 
HeLa-specific 1-13 program on the nucleofector machine. 3 pg of each siRNA 
(Lamin A/C, HsMafl pooled, Brfl siRNA-1, BrflsiRNA-2 or a pool of both 
Brfl siRNAs) was used per reaction cuvette. Each reaction was split evenly 
into a 6 -well plate, with the addition of fresh media. Cells were harvested 48 
hours later. siRNA sequences were as follows:
Lamin A/C [sense: r(CUGGACUUCCAGAAGAACA)dTdT; antisense:
r(UGUUCUUCUGGAAGUCCAG)dTdT]
Brfl siRNA-1 [sense: r(GGAUGCAAUUGAGAUUGAA)dTdT; antisense: 
r(UUCAAUCUCAAUUGCAUCC)dTdG]
Brfl siRNA-2 [sense: r(GGAGGAGGUUGAAGGUGAA)dTdT; antisense: 
r(UUCACCUUCAACCUCCUCC)dAdG]
HsMafl siRNAs (1 pg of each siRNA was used for a pool of 3 pg total):
Target 1 [sense: r(GAUGGCGGGAGAUGAUAAA)dTdT; antisense:
r(UUUAUCAUCUCCCGCCAUC)dTdT]; Target 2 [sense: r(GUCAUGAAU 
UCAGCCGAGA)dTdT]; antisense: r(UCUCGGCUGAAUUCAUGAC)dTdT] 
Target 3 [sense: r(AUGCAGUCAACUGCAGCCU)dTdT]; antisense:
r(AGGCUGCAGUUGACUGCAU)dTdT
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All siRNA sequences were designed and synthesised by Qiagen. “Scrambled 
siRNA” is a non-targeting negative control duplex known to have no limited 
sequence similarity to known, genes. The sequence is not provided when 
purchased.
2.10.2 HeLa and MCF-7 siRNA proliferation rate assays
Cells were grown in normal growth medium to -80% confluency before 
nucelofection. 1X10^ cells and 3 pg siRNA were used per reaction, following 
the manufacturer’s instructions for nucleofection, the correct solutions, and 
program, above. After electroporation, cells were pooled Into 45 mis fresh 
media, gently pipetted up and down, and aliquotted into four 1 0  cm culture 
dishes. This allowed for even distribution of the cells. Time 0 was coimted 
with a haemocytometer by immediately counting the cells placed within a 1 0  
cm plate. The cells were grown for a period of 72 hours, replacing medium 
after 2 days. Total numbers of dead cells were calculated by trypsinizing cells 
as discussed previously, and resuspending in DMEM and trypan blue (Sigma), 
although these counts averaged less than 1 cell per haemocytometer (Sigma), 
and therefore were dismissed. Counts were made in triplicate with at least two 
10 cm plates being used for each condition examined. Viable cell counts were 
plotted against day number to show proliferation rates of the cells, and the 
changes from time 0 to 72 hours plotted as a percentage change.
2.10.3 pTRE2.hyg.HA.HsMafl proliferation rate analysis
Cells were grown to -80% confluency before plating. 2.0 X 10^  cells were 
plated per 10 cm plate. Cells counted at time point 0 were counted, via a 
haemocytometer, immediately after application to the 10 cm plate. 24 hours
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after plating, half the cells were induced by the addition of 1 mg/ml 
doxycyclin, and fresh media was applied to all cells. Cells were counted at 96 
and 120 hours after induction. Counts were made in triplicate, with at least 
two 10 cm plates being counted for each condition. Viable cell counts were 
plotted against day number to visualise proliferation rates graphically.
2.11 Tagetitoxin experiments
2.11.1 Direct application of tagetitoxin to NIH 3T3 cells
Commercially made tagetitoxin, Tagetin™, was purchased fi*om Epicentre®. 
NIH 3T3 cells were seeded at 1 X 10^  per well of a 6 -well culture plate, and 
were left at normal culture conditions for 24 hours. 45 pM Tagetin™ was then 
applied to half of the wells, along with 500 pi of normal culture media. After 2 
hours incubation cells were harvested for RNA.
2.11.2 RNA pol HI in vitro transcription assay
In vitro transcription of class III genes was reconstituted using 20 pg of HeLa 
nuclear extract to provide the basal pol III transcription components. This was 
supplemented with the addition of 250 ng of plasmid DNA to supply a specific 
pol III template and reactions were carried out in a 25 pi volume with a final 
concentration of 12 mM HEPES pH 7.9, 60 mM KCl, 7.2 mM MgClz, 0.28 
mM EDTA, 1.2 mM DTT, 10% (v/v) glycerol, 1 mM creatine phosphate, 0.5 
mM each of rATP, rCTP and rOTP and 10 [a-^^P] UTP (400 mCi/mmol)
(Amersham). In one half of the reaction tubes, HeLa nuclear extract was 
incubated for 10 minutes at 30°C with 2.5 pi of 100 pM Tagetin'*’"^  before the 
addition of the nucleotides, radioisotopes, etc, listed above. The other half of 
the reaction tubes (the control tubes) were supplemented with 2.5 pi sterile
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distilled water and incubated for 10 minutes at 30°C. After this 10 minute 
incubation, transcription components were assembled on ice and the reaction 
was performed at 30°C for 1 hour. Transcription was terminated by the 
addition of 250 pi of 1 M ammonium acetate/0.1% SDS containing 20 pg of 
yeast tRNA which acts as a carrier for the synthesised RNA. Phenol- 
chloroform extraction of the samples was performed to remove protein and 
DNA by adding 250 pi of a 25:24:1 ratio solution of PhOH/CHCls/IAA. The 
samples were vortexed, microcentrifuged at 13,000g for 5 minutes and 200 pi 
of the upper aqueous layer was then transferred to a fresh eppendorf tube 
containing 750 pi of 96% ethanol in order to precipitate the RNA. The 
samples were thoroughly mixed by repeated inversion, and left at - 2 0 °C 
overnight before being microcentrifuged at 13,000g for 2 0  minutes to pellet the 
precipitated RNA. The supernatant was carefully removed and 750 pi of 70% 
ethanol was added to each sample to wash the pellet. This was also carefully 
removed to avoid dislodging the pellet and the samples were heated at 37°C for 
5 - 1 0  minutes to dry. 4 pi of formamide loading buffer (98% formamide, 10 
mM EDTA pH 8.0, 0.025% bromophenol blue, 0.025% xylene cyanol FF) was 
added to each sample, which was then vortexed for 2 0  minutes to ensure the 
RNA was fully redissolved. 2 pi of each sample was loaded on a pre-run 7% 
polyacrylamide sequencing gel containing 7 M urea and 0.5 x TBE (45 mM 
Tris, 45 mM boric acid, 0.625 mM EDTA pH 8.0) after being boiled at 100°C 
for 2 minutes and quenched on ice. Electrophoresis was performed at 40 W for 
1 hour in 0.5 X  TBE before being dried and exposed to autoradiography film in 
order to detect the radiolabelled transcripts.
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2.11.3 Plasmid templates used in the in vitro transcription assay
The plasmid templates used for the in vitro transcription assay were as follows: 
pVAi is a 221 bp SaB-Bal\ fragment of adenovirus 2 DNA containing the VAi 
gene subcloned into pUC18 (Dean and Berk, 1988); pLeu is a 240 bp EcoBl- 
HindUl fragment of human genomic DNA carrying a tRNA*^ ”^ gene, subcloned 
into pAT153 (McLaren and Goddard, 1986); PHu5S3.1 is a 638 bp Bamïîl- 
Sacl fragment of human genomic DNA containing a 5S rRNA gene, subcloned 
into pBluescript SK+; and the pol I template was pHrP2 (Lescure et al., 1994), 
which has an 800 bp Sau3A fragment of the human rRNA promoter, from -411 
to +378, subcloned into RamHl-linearised pUC9.
2.11.4 Application of tagetitoxin to NIH 3T3 cells by heat shock
Cells were seeded at 1 X 10^  per well of a 6 -well culture plate and left at 
normal culture conditions for 24 hours. Medium was aspirated off and 500 pi 
of fresh media was applied to cells. 45 pM Tagetin™ was then applied to half 
of the cells, and incubated for 60 minutes at 37°C. Cells were then heat- 
shocked for 25 minutes by placing them in an incubator at 45 °C. Cells were 
then allowed to recover for 40 minutes at 37°C before RNA extracts were 
made.
2.11.5 Nucleofection of HeLa cells with tagetitoxin
Electroporation of cells with Tagetin™ was performed in the same mamier as 
the siRNA experiments, per the manufacturer’s instructions, using Cell Line 
Nucleofector™ Kit R and program 1-13. 1 X 10  ^cells were used per reaction 
cuvette, along with distilled sterile water as a control or 30 pi (22 pM) 
Tagetin™. The nucleofected cells were added drop wise to 2 mis media that
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had been pre-incubated in 6 -well culture plates. Cells were harvested 48 hours 
later for RNA extracts.
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Decreasing Brfl levels by small interfering 
RNA decreases RNA polymerase III 
transcription
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3.1 Introduction
3.1.1 Saccharomyces cerevisiae and Brfl discovery
Eai'ly research on Brfl -containing transcription factor -BIB was mostly done 
in S. cerevisiae. Klekamp and Weil and Kassavetis et al. purified TFIIIB and 
found that a fraction was capable of reconstituting tRNA transcription when 
incubated with TFIIIC and pol III (Kassavetis et ah, 1991a; Klekamp and 
Weil, 1986). Further chromatography split this fractionation into two 
constituents, designated B’ and B,” and both components proved essential for 
tRNA transcription when added to TFIIIC and pol III (Kassavetis et a l, 
1991a). To examine these fractions further, Bartholomew et a l, probed the 
polypeptide composition of TFIIIB by photocrosslinking and detected two 
polypeptides of 70 and 90 kDa (Bartholomew et a l, 1991). The 70 kDa 
component was found in the B’ fraction of TFIIIB, while the 90 kDa 
component was found in the B” fraction (Kassavetis et a l, 1991a).
These discoveries heralded the cloning of the Brfl gene by three groups, 
encoding a protein of 596 amino acids with a predicted molecular mass of 
67kDa (Buratowski and Zhou, 1992; Colbert and Hahn, 1992; Lopez-De-Leon, 
1992). Extracts deficient in Brfl are defective in pol III transcription but can 
be reconstituted by the addition of recombinant Brfl (Colbert and Hahn, 1992). 
Mutation of the Brfl gene showed a decrease in class III gene expression 
(namely tRNA and 5S rRNA), but had no effect on in vivo expression of class I 
or class II genes (Lopez-De-Leon, 1992). This discovery implied that Brfl may 
be needed for transcription complex assembly on class III genes, but is not 
necessary on class I or II genes.
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As stated in the introduction, Brfl was named to reflect its homology with 
TFIIB. Yeast Brfl displays 23% identity and 44% similarity to TFIIB in its 
320 N-terminus residues and two imperfect repeats of 76 amino acids in the 
amino region (Buratowski and Zhou, 1992; Colbert and Halm, 1992; Lopez- 
De-Leon, 1992). The C-terminal half is dissimilar, although three regions of 
conservation have been noted and designated as homology regions I, II and III 
(HI, HII, HIII) (Khoo et a l, 1994). These regions might later prove to be 
significant sequences, possibly determining the function of Brfl through 
mechanisms such as phosphorylation.
3.1.2 Brfl interactions within the pol III initiation complex
3.1.2.1 TBP
Because TFIIB and TBP were known to interact, it was postulated that Brfl 
might interact with TBP in a similar manner (Ha et a l, 1993). Indeed, further 
analysis by mutagenesis showed that Brfl contains two separate TBP-binding 
domains that interact with opposite faces of complexed TBP-DNA (Colbert et 
a l, 1998; Kassavetis et a l, 1998). While Brfl binds to the TFIIIC-tRNA gene 
complex weakly, the interaction is made stable by two binding sites on TBP, 
the TBP- Brfl complex being extremely stable (Kassavetis et a l, 1992). One 
binding site is assigned to the N-terminal half, in the conserved direct repeat 
region, while the C-terminal half of Brfl (namely the HII domain) arbitrates 
another interaction with TBP (Andrau et a l, 1999; Colbert et a l, 1998; Khoo 
et a l, 1994). This was proved further when in vitro experiments demonstrated 
that recombinant TBP and Brfl adequately reconstitute all known properties of 
the B’ fraction (Kassavetis et a l, 1992), mimicking the properties of the
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proteins isolated in the B’ complex from the same laboratory one year earlier 
(Kassavetis et a l, 1991a).
3.1.2.2 TFIIIC
Brfl contacts DNA-bound TFIIIC by protein-to-protein interactions, therefore 
recruiting TFIIIB to genes containing type I or II promoters. In mammalian 
cells, TFIIIC binds to Brfl through its 63, 90, and 102 kDa subunits (Hsieh et 
al, 1999b; Hsieh et a l, 1999a), while in yeast TFIIIC subunit Tfc4 binds to 
Brfl (Kassavetis et a l, 1992). Once recruited to a promoter through TFIIIC, 
TFIIIB locks to the promoter in an incredibly stable complex (Kassavetis et a l , 
1990). This binding is important as it allows TFIIIC to act as a “positioner,” 
dictating the optimal location for TFIIIB on the promoter (Joazeiro et a l, 
1996).
3.1.2.3 Pol III
Wemer et a l, used a two-hybrid system with expression monitored by the 
GALl-/acZ reporter to investigate protein-protein interactions between various 
pol III subunits and Brfl (1993). Pol III subunit C34 was found to interact 
with Brfl, but not subunits C82, C34, or C31. This discovery places even 
more importance on the TFIIIB subunit Brfl, as it shows that this interaction 
directs pol III to its associated genes, influencing transcription.
3.1.2.4 Bdpl
Brfl plays a critical role in holding TFIIIB together through its interactions 
with not only TBP, but also Bdpl. Binding of Brfl and Bdpl to the TBP- 
TFIIIC-DNA complex is extremely important, cementing the protein to protein
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interactions, helping to determine the physical properties of the TFIIIB-DNA 
complex, and actually bending the DNA (Colbert et a l, 1998; Kumar et al, 
1997; Shah et a l, 1999). Interactions of Brfl, held together by Bdpl, help to 
protect the DNA from DNase I (Shah et a l, 1999). Brfl and Bdpl have 
overlapping binding sites on Tfc4 (TFIIIC), competing for binding in TFIIIC- 
directed TFIIIB complex assembly (Liao et al, 2003).
By using Brfl fragments and photochemical protein-DNA cross-linking, 
Kassavetis et a l, established the sites of Brfl attachment to Bdpl (Kassavetis 
et a l, 1998). The TBP- and Bdpl- interacting domains of the C-terminal half 
of Brfl both reside within the amino acid 435- 45 segment, which contains Brf 
homology region 2. This region of Brfl is necessary and sufficient for Bdpl 
recruitment to a stable DNA complex (Kassavetis et a l, 1998). Although it 
was found to be a weaker interaction, the N- proximal half of Brfl also binds 
to Bdpl (Kassavetis et a l, 1998; Khoo et a l, 1994). Both halves of Brfl are 
able to recruit Bdpl to the TFIIIB-DNA complex (Kassavetis et a l, 1998). 
Further recent analysis from Kassavetis et al showed that the principal 
attachment site of Brfl for Bdpl is a 6 6 -amino acid segment of Brfl, serving 
as a two-sided adhesive surface, the side chains projecting away from its 
interface with TBP anchoring Bdpl binding (2006).
Brfl and Bdpl also have connected roles during mitosis through 
phosphorylation. Fairley et al observed that hyperphosphorylation of Brfl 
during mitosis may reduce its affinity for Bdpl, allowing the release of Brfl 
and thereby inhibiting transcription (2003). Therefore, even though the
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structures of Bdpl and Brfl are very different, their roles within the 
transcription apparatus seem to be closely connected.
3.1.3 Brfl is an influential binding sight for tumour 
suppressors, oncogenes, and kinases
(Summarized in Figure 3.1),
3.1.3.1 Tumour suppressors RB and p53
Brfl emanates further importance in its role as a influential binding protein by 
directly binding with knovm tumour suppressors RB and p53. Recombinant 
and endogenous RB was shown to bind to Brfl in pull-down and 
immunoprécipitation experiments (Chu et al, 1997; Larminie et a l, 1997). 
This binding disrupts the interaction between TFIIIB and TFIIIC, dissociating 
TFIIIB from its functional association with TFIIIC (Sutcliffe et a l, 2000). By 
RB binding to TFIIIB, RB is able to function and instil its tumour suppressor 
properties on pol III transcription, keeping levels of pol III transcription under 
check. This is vital, when considering that mutations in the Rb gene are found 
in many human cancers, while other proportions contain the wild type Rb but 
its function is disrupted (Grana et a l, 1998; Herwig and Strauss, 1997; 
Mulligan and Jacks, 1998; Weinberg, 1995).
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Figure 3.1. Brfl is an influential binding site for tumour suppressors, 
oncogenes and kinases.
Brfl binds to pol III subunit C34, while TFIIIC binds to Brfl through its 63, 
90, and 102 kDa subunits. TBP binds with both the C- and N-terminal halves 
of Brfl. Bdpl and Brfl compete for binding sites on TFIIIC. Residues 1-262 
of c-Myc, encompassing its transactivation domain, were found to bind to 
Brfl. When p53 is bound to TFIIIB, TFIIIB is unable to interact with TFIIIC 
or be recruited to pol III templates. Hyperphosphorylaton of RB causes 
dissociation from TFIIIB, therefore derepressing transcription. ERK and CK2 
both phosphorylate Brfl.
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As stated previously, when p53 is bound to TFIIIB, TFIIIB is unable to interact 
with TFIIIC or be recruited to pol III templates (Crighton et a l, 2003). p53 
was found to specifically bind Brfl during immunoprécipitations in both 
endogenous and in vitro experiments in amounts comparable to p53- TBP. 
Interestingly, many missense substitution mutations (75%) found to be 
expressed in human malignancies with mutant forms of p53 are located in the 
core domain- the very region that is required for p53 regulation of TFIIIB 
(Bullock et a l, 2000; Hollstein et a l, 1994; Stein et a l, 2002a; Stein et a l, 
2002b).
This fiirther substantiates Brfl as an important subunit in the transcription 
factor- IIIB complex, as it would argue that loss or mutation of p53 in the 
domain that binds Brfl will contribute to the derepression of TFIIIB, and 
hence the deregulation of pol III transcription in a substantial portion of human 
malignancies.
3.1.3.2 Proto-oncogene c-Myc
Investigations by Gomez-Roman et a l , showed that c-Myc is able to directly 
activate pol III transcription by binding to Brfl (2003). Residues 1-262 of c- 
Myc, encompassing its transactivation domain, were found to bind to Brfl 
through protein-protein interactions in vitro using gluthathione S- transferase 
(GST) fusion proteins. Endogenous experiments demonstrated that c-Myc also 
fractionates with TFIIIB activity on several columns, binding stably and 
specifically (Gomez-Roman et a l, 2003).
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The binding of c-Myc to Brfl gains considerable importance when the 
implications of this binding were discovered. c-Myc-TFIIIB binding potently 
stimulates transcription of pol III transcripts tRNA^®“, tRNA^ "^^  and 5S rRNA 
within cells (Gomez-Roman et a l, 2003; Hirst and Grandori, 2000). This 
increase in biosynthesis would be expected to impact strongly on cell growth, 
as c-Myc also targets genes transcribed by pol II that are involved in 
metabolism and translation (Boon et a l, 2001; Rosenwald, 1996). Indeed, 
deregulation of c-Myc was found to be a commonality in some Burkitt’s 
lymphomas, neuroblastomas and colon carcinomas (Dang, 1999; Nesbit et a l, 
1999). In summary, Brfl-c-Myc binding contributes to the deregulation of pol 
III transcription, which in turn may influence c-Myc’s role in growdh control.
3.1.3.3 Kinases ERK and CK2
ERK is connected to pol III transcription not only tlirough its binding with 
TFIIIB, but also through c-Myc activation, causing a rapid increase in 
translation and growth (Rosenwald, 1996; Schmidt, 1999). ERK is able to co- 
regulate both pol I and pol III, where the phosphorylation of UBF in the pol I 
system can regulate DNA-binding properties, while the phosphorylation of 
TFIIIB enhances its ability to bind to TFIIIC and pol III. This coordinates the 
production of pol I products 5.8S, 188 and 28S rRNA and pol III products 58 
rRNA and tRNA, which are required in equimolar quantities within the cell 
(Felton-Edkins et a l, 2003a; Schmidt, 1999; Stenfanovsky et a l, 2001).
The phosphorylation of TFIIIB by ERK is applied to the Brfl subunit and ERK 
must be activated in order for it to bind (Felton-Edkins et a l, 2003a). Once 
activated in the cytoplasm, ERK must translocate to the nucleus to interact
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with TFIIIB. Further analysis by Felton-Edkins et al. by mutations of Brfls 
ERK phosphorylation site or putative docking domain showed a significant 
reduction of pol III activation in fibroblasts (2003a). However, when ERK 
activity was blocked by a MEK inhibitor, Brfl phosphorylation was only 
partially reduced, making it likely that another kinase, such as CK2, is required 
for the uppermost levels of pol III transcription (Felton-Edkins et a l, 2003a; 
Ghavidel et a l, 1999; Ghavidel and Schultz, 1997; Johnston et a l, 2002).
The ubiquitous protein kinase CK2 was found to cofractionate and 
coimmunoprecipitate with TFIIIB, namely the Brfl subunit, in yeast and 
mammalian cells (Ghavidel and Schultz, 1997; Johnston et a l, 2002). As with 
ERK, CK2 promotes interactions between TFIIIB and TFIIIC and 
phosphorylation by CK2 may be required for Brfl to interact with TFIIIC 
(Johnston et a l, 2002). CK2 was also found to phosphorylate the HII region of 
Brfl (L.E. Mitchell and R.J. White, unpublished observations).
As abnormal CK2 activity is linked to a variety of human cancers (Faust et a l, 
1996; Munstermann et a l, 1990; Notterman et a l, 2001) and CK2 activation of 
pol III transcription through phosphorylation of Brfl stimulates the synthesis 
of pol III products (Johnston et a l, 2002), the relationship between Brfl and 
CK2 is clearly important.
3.1.4 Brfl and human papillomavirus 16 (HPV16)
The most prevalent cases of cervical cancers were found to correlate with 
infection by HPV 16 (zur Housen, 2000). The pathway a cervical cell follows 
to transformation includes the expression of oncogenes E6 and E7, which serve
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to inactivate tumour suppressors p53 and Rb (Dyson et al., 1989; Munger et 
a l, 1989). Futhermore, infection by HPV 16 was linked to elevated Brfl 
mRNA in cervical biopsies tested by Daly et al. which does not result from 
inactivation of RB or p53 (2004). In cervical cells Brfl levels are limiting for 
production of tRNA and 5S rRNA, making it a major player in a cell’s 
biosynthetic capacity. These results provided the first evidence that a virus 
may induce Brfl expression, although the mechanism still remains elusive.
3.1.5 Small interfering RNA (siRNA)
3.1.5.I siRNA and evolution
It is believed that RNA-triggered silencing arose from an organism’s need to 
survive without unwanted gene expression and to keep transposons and viruses 
at bay (reviewed in Fire, 2001). Global “policing” mechanisms include not 
only RNA interference (RNAi), but also encompass diverse pathways such as: 
preferential méthylation of transposon sequences, repeat-dependent silencing, 
and nonsense-mediated mRNA decay. These pathways all share a 
commonality in that in each case a nucleic acid conformation that is not 
associated with normal gene expression is used by the organism to detect 
potentially detrimental situations. One response to this situation may be to 
stop the production or expression of potentially detrimental RNAs.
Both plants and animals were found to express genes that encode short forms 
of fold-back dsRNA (Bartel, 2004). These dsRNAs are processed into 
microRNAs (miRNAs, discussed below), which are evoiutionarily conserved. 
In plants these miRNAs frmction to guide the cleavage of sequence- 
complementary mRNAs, but in animals these miRNAs take on a different role,
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inhibiting translation by targeting partially complementary sequences located 
within the 3 ’ untranslated region (UTR) of mRNAs (reviewed in Meister and 
Tuschl, 2004).
Observations of the underlying mechanisms involved in gene silencing in 
plants, fungi, and animals, reveal remarkable similarities that emphasize a 
common ancestor (Mello and Conte, 2004). Gene silencing was first 
discovered in plants, where it was known as post-transcriptional gene 
silencing, and many of the teclmiques used to reveal the components within 
this system have been used with similarity within the mammalian system 
(Baulcombe, 2004; Meister and Tuschl, 2004).
3.1.5.2 The discovery of RNAi in mammals
The importance of RNAi and its implications in research applications is 
emphasized by the reward of the 2006 Nobel Prize in Physiology or Medicine 
given to Andrew Z. Fire and Craig C. Mello for their work with the nematode 
Caenorhabditis elegans. The Mello research group found that double-stranded 
RNA (dsRNA) was a potent trigger for RNAi in C. elegans, and this 
interference could spread from tissue to tissue as well as be passed through the 
sperm or egg for up to several generations (Fire et a l, 1998). This discovery 
created a new type of research tool that could be used to decode gene function. 
RNAi is now used to manipulate gene expression experimentally as well as 
probing gene function on a genome-wide scale. After Fire et a l  discovered the 
RNAi trigger, Tuschl and colleagues showed that transfection of mammalian 
cells with host RNAs could induce the sequence-specific RNAi pathway.
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which surmounted the obstacle of using RNAi as a genetic tool in mammals 
(Elbashir et a l, 2001a).
3.1.5.3 The mechanism of gene silencing by siRNA
There are three types of naturally occurring small RNA that differ according to 
their origins: siRNAs, miRNAs and repeat-associated short interfering RNAs 
(rasiRNAs) (reviewed in Meister and Tuschl, 2004). dsRNA can be produced 
naturally from viruses by RNA-templated RNA polymerization, or by 
hybridization of overlapping transcripts which give rise to siRNAs or 
rasiRNAs. dsRNA hairpins that are formed from endogenous transcripts that 
contain inverted repeats are later processed into miRNAs. Both dsRNAs and 
siRNAs have been used as a tool for gene silencing in vivo.
The mechanism of silencing by siRNA was first found in plants, where short 
RNAs from 20-25 nucleotides long were produced from a RNAi-related 
process (Hamilton and Baulcombe, 1999). Deciphering this mechanism 
further, in the same year an RNAi reaction was reconstituted in vitro using 
fruitfly extracts. Elbashir et a l discovered that the long dsRNA were chopped 
up into short RNAs with two 21-nucleotide strands of RNA in a staggered 
duplex, with 19 nucleotides of dsRNA and two unpaired nucleotides at the 
ends (2001b). These experiments led to a wave of research uncovering the 
mechanism of RNAi, although there is still much to be revealed, especially 
within the mammalian system.
The first step in the RNA-interference pathway (designated the initiation 
phase) involves the ribonuclease-III enzyme Dicer (DCR), which processes
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long dsRNAs into 21-23-nt siRNAs that have 5’ phosphates and 2-nucleotide 
3’ overhangs during the initiation step of RNAi (Bernstein et a l, 2001) (see 
Figure 3.2).
In C elegans and mammals a Dicer-interacting dsRNA-binding domain 
(dsRBD) protein is thought to allow Dicer to recognize different sources of 
dsRNAs, however, this protein (or proteins) has yet to be identified. Many 
organisms contain more than one Dicer gene, each Dicer preferentially 
processing dsRNAs that come from a specific source, although in mammalian 
systems there is only one Dicer gene (Meister and Tuschl, 2004). Micro RNAs 
do not use Dicer, but instead use another endonuclease named Drosha.
DCR has been linked to the Argonaute (Ago) proteins, a family of proteins that 
are characterized by the presence of two homology domains, PAZ and PIWI. 
DCR binds directly to Ago proteins AG02 and PIWI through an RNase-III 
domain of DCR and the PIWI domain of the Ago proteins (Tahbaz et al, 
2004). The 21 to 23nt duplexes are then incorporated into a nuclease- 
containing multi-protein complex named RNA-induced silencing complex 
(RISC) (Hammond et a l, 2000). The exact components of this complex 
remain elusive, however it is hypothesized that AGOl and AG02 are involved 
in the 160 kDa minimal RISC mammalian complex, functioning to target-RNA 
binding and cleavage (Martinez and Tuschl, 2004; Meister et a l, 2004).
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Figure 3.2 Mechanism of RNAi in mammalian systems. (Adapted 
from Aigner, 2005).
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Every RISC complex (in a variety of species) has been found to contain at least 
one Argonaute protein. The PAZ domain of Ago is implicated in RNA 
binding, recognizing the terminus of the base-paired helix of the siRNA 
duplexes, while the PIWI domain provides RISC with effector-nuclease 
activity (Meister et a l, 2004; Song et a l, 2004). The PAZ domain also 
ensures that unrelated RNA is not processed into RISC, by only letting RNA 
with 2-nucleotide 3’ overhangs be incorporated (Lingel et a l, 2004). In 
addition to Ago proteins, fragile X mental retardation protein (FMRP) was 
found to incorporate with siRNAs into the RISC complex, although the 
function of this protein is still unknown. RISC assembly is ATP-dependent, 
which reflects the need for energy for the unwinding of siRNA duplexes and/or 
spatial changes within the RISC complex (Nykânen et a l, 2001).
Synthetic 21-nt long siRNAs are thought to bypass Dicer, as they still function 
as potent RNAi triggers and do not imdergo dsRNA processing (Elbashir et a l , 
2001a). Relative thermal stability dictates rules for RISC entry for non­
processed siRNAs (Khvorova et al., 2003). The RISC incoiporated “guide” 
strand becomes the strand that has its 5’ terminus at the end of the siRNA 
duplex, which is less stably base-paired than the other strand. The non­
incorporated strand is simply discarded.
Once RISC has unwound the siRNA, cleavage of the target mRNA in the 
middle of the complementary region, ten nucleotides upstream of the 
nucleotide paired with the 5’ end of the guide siRNA occurs (Elbashir et al, 
2001b). This process was found to be ATP-independent, however multiple 
rounds of cleavage functions more efficiently in the presence of ATP. This
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suggests that a RNA helicase yet unknown might be cleaving the siRNA and 
working as RISC’s endonuclease subunit (Hutvagner and Zamore, 2002). This 
cleavage is a hydrolysis reaction yielding 5’ phosphate and 3’ hydroxyl termini 
which requires magnesium ions and parallels the reaction in which Dicer 
generates siRNA duplexes from dsRNA precursors (Martinez and Tuschl, 
2004). It is hypothesized that Ago proteins may act as nucleases, performing 
the cleavage reactions of the target mRNA, however in humans only Ago2 but 
not Agol and Ago3 have been found to have nuclease activity (Ma et a l, 
2004). Although there have been many recent advancements in the research 
surrounding RNAi, it is clear that there is still much to be uncovered.
3.1.5.4 siRNA: an indispensable tool
siRNA has opened the doors for the testing of individual gene function. 
Indeed, in C  elegans at least 19,000 genes (nearly all) have been analysed, and 
now similar strategies are being used to ascertain gene function in various 
other organisms. Traditionally gene function is analysed by using a ‘forward 
genetic’ approach, identifying an organism with abnormal physical or 
behavioural traits, and then isolating the mutant gene(s). This technique is 
usually limited to organisms that reproduce rapidly. In the mammalian system, 
‘reverse genetic’ approaches allow researchers to knock out a specific gene and 
later identify its function (i.e. knockout mice), although these methods can be 
laborious and expensive. In contrast, RNAi allows the option of analyzing 
many silenced genes at once, can be less costly, and offers a higher- 
throughput.
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Upon initial use within the manmialian system, the drawback of siRNA 
seemed to be that the effects were only transient, as mammals lack the 
mechanisms that amplify silencing in worms and plants. This problem was 
soon solved, when 500-base-pair dsRNA expressed In cell lines was found to 
stably suppress targeted genes (Paddison et a l, 2002). However, a caveat to 
this approach is that it could only be performed in cell lines that lacked generic 
responses to dsRNA, such as the RNA-dependent protein kinase (PKR.) 
pathway. Fortunately, another technique in which short hairpin RNAs 
(shRNAs) can be expressed from pol III promoters to induce a stable 
suppression of target genes has been found (Brummelkamp et a l, 2002). 
Stable expression allows for the observation of induced phenotypes over longer 
time spans and stable cell lines can be assayed in vitro or in vivo. When 
looking from the therapeutic standpoint, shRNAs can be used to deliver gene 
silencing effects via gene delivery vehicles to target problem genes, such as an 
activated oncogene.
3,1.5.5 siRNA: potential pitfalls
Although there are many benefits in using siRNA as a research tool, there are 
also some potential problems, most of which can be avoided if experiments are 
performed diligently. RNAi has been found to target genes and proteins that it 
was not designed to target, and scientists are currently trying to determine how 
widespread the effects are, how they can be avoided, and why they occur 
(Couzin, 2004).
An example of this occurrence is found in laboratory experiments performed 
by Sledz et al. and many others working on RNAi (Bridge et al, 2003; Judge
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et a l, 2005; Sledz et al, 2003). Assays determined that when GAPDH siRNA 
(a commonly used control siRNA) was transfected into mammalian cells, 
responding GAPDH mRNA levels were decreased but there was an 
upregulation of Statl, a component of the Jak-Stat signalling pathway resulting 
in interferon mediated activation. The interferon system has been determined 
as an off-target effect of some siRNAs. The interferon system is an innate 
immune response that can be activated by dsRNA. This system is commonly 
the first line of defence against viral infection, where upon infection cytokines 
are stimulated to start a complex signalling cascade, culminating in the 
induction of interferon-stimulated genes within the nucleus. Sledz et al found 
that by transfecting various 21-bp dssiRNAs, interferon-mediated activation of 
the Jak-Stat signalling pathway occurred (2003). The side effects are not only 
cause for concern when using RNAi as a basic research tool, but also for use in 
therapeutics when an immune response by the interferon system would be 
detrimental to the target.
Although there seems to be many ways in which siRNAs can provoke off- 
target effects, many of these mechanisms remain elusive. The pertinent 
question is: how can laboratories avoid or minimize these off-target effects 
when possible? Currently, this question seems to have at least two possible 
answers, focusing on the specific design of the siRNA and the concentrations 
of siRNA introduced into the cell or organism.
Biotechnology companies can chemically synthesize siRNA against a target 
sequence after picking a sequence that has undergone a stringent algorithm of 
design rules based on current research. These design rules are also used in
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“self-made” siRNAs, in which a target gene is chosen and a target sequence is 
picked using similar recommendations, usually with the aid of an online design 
tool. The siRNAS are then made via in vitro transcription from 
oligonucleotide templates (Brown et a i, 2002). Below is a table depicting a 
number of current design criteria, and why each characteristic is important in 
siRNA design (Table 3.1). However, even though a siRNA may meet all 
current design criteria, the off-target effects still may occur, making further 
testing of the siRNA critical.
Researchers have found that the concentration of siRNA is an important 
determinant of its efficacy. Three independent labs determined that off-target 
effects are least likely to occur when concentrations between 1 and 30 nM are 
used (Chi et a l, 2003; Jackson et a l, 2003; Semizarov et a l, 2003). However, 
even when these concentrations are used, genome-wide studies show that off- 
target effects can still occur (Jackson and Linsley, 2004; Snove and Holen, 
2004).
Why o ff  target effects occur continues to remain a matter of debate. One 
possibility is that mammalian cells may be mistaking foreign siRNAs for 
microRNAs, because both siRNAs and microRNAs use many of the same 
enzymes within their pathway (Couzin, 2004). There may be a fine line 
between triggering one pathways versus another, and the microRNA pathway 
is considered much less specific, targeting sequences that only partly match 
their own.
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Table 3.1 Common techniques used in siRNA design
siRNA Characteristics Rationale
The sense strand of the siRNA is 
the same sequence as the target 
mRNA sequence, except lacking 
the 5’ AA sequence
Facilitates binding of the target 
sequence, as the antisense strand 
binds to the target gene
Sequence of 21nt dsRNA with 3’ 
overhanging dimers of thymidine 
uridine
May enhance nuclease resistance 
in the cell culture medium and 
transfected cells ^
AA and dovmstream 19 
nucleotides are compared to an 
appropriate genome database
Decreases risk of off-targets as 
sequence is checked for 
homology to other genes
siRNA target sequences should be 
~80 nucleotides from the AUG 
start codon on the target RNA
This criterion is controversial. 
Elbashir et al. suggests that this 
may facilitate binding of the 
“Sheer” apparatus % while other 
groups have found that the 
location of the siRNA target site 
is not a predictable indicator of 
siRNA silencing activity^
Hign GC content at 5’ end 
Low GC content at 3’ end
Sense strand is preferentially 
loaded into RISC^
No long repeats at siRNA ends 
that are complimentary
May form inactive hairpins
^Elbashir et al. 2001a, ^Brown et a/.2003, ^Ambion, Inc.
76
Chapter 3
Scientists often use microarrays to look for off-target effects, but this technique 
could provide ineffective because microarrays only show gene expression 
levels and not protein levels. If the siRNA happens to be triggering the 
microRNA pathway, microRNAs may change how RNA is translated into 
protein.
Peter Linsley’s group found that the specific part of the siRNA that was 
contributing to weak sequence matching between siRNAs and genes is the 5’ 
end (Jackson et a l, 2003). If this 5’ end matches a sequence in another gene, 
there may be a risk of off-target binding. Strengthening this research, Schwarz 
et a l, reported that siRNAs with certain sequences and structures may unravel 
in different manners and the differences in this unwinding may determine how 
well they target the right gene (Schwarz et a l, 2003). Nevertheless, with 
stringent controls, data from siRNA research may be convincing and certainly 
influential.
In June of 2003 the editors of Nature Cell Biology published an editorial listing 
possible controls that could be utilized during siRNA experiments. This list is 
based on a May 2003 Horizon symposium on RNA and provides clear 
explanations on proper uses of RNAi controls and standards that must be in 
place for publications. Currently, the rescue control is regarded as the most 
pertinent control. This involves rescue by expression of the target-gene in a 
form unaffected by the siRNA, An example of this is a vector-based siRNA 
system, namely an inducible system. Expression of a target gene could be 
silenced by inducing production of siRNA, which could then be halted to 
reveal a return to a normal phenotypic state. This type of control may not
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always be possible, however, as some genes (if expressed in leaky induction 
systems) may cause death of the cell or organism. In the cases where rescue 
controls are impossible, basic controls including reduction of mRNA and 
protein levels are necessary and termed ‘classical’ RNAi. Quantitative 
controls are also highly desired, whereby titration to the lowest possible level 
reduces the chance of side effects and provides gradual data on the effect of the 
siRNA. This is important because the RISC complex has shovm to be 
saturable in some settings (Haley and Zamore, 2004). Other important controls 
include mismatch or scrambled siRNAs and testing multiple siRNAs designed 
against different sites on the same target gene.
3.1.5.6 siRNA used in therapeutics
The prospects of using RNAi for therapy are promising. Possible disease 
targets include conditions that arise from aberrant gene expression including; 
RNA viruses (such as HIV), cancer, and neurode generative disorders, 
although this list is not all-encompassing (Boden et a l , 2004; Brummelkamp et 
al, 2002; Kao et a l, 2004; Wilda et a l, 2002). Boden et a l  demonstrated the 
use of a retroviral vector to transfer shRNA expression cassettes genetically 
into human cells (Boden et a l, 2004). Using a specific shRNA to target the 
viral transactivator protein tat, the group reported HIV-1 replication decreased 
by greater than 95%. In addition to silencing pathogenic viral genes, siRNAs 
have been used to effectively knockdown expression of oncogenes such as 
BCR-ABL (Wilda et a l, 2002) and K-RAS (Brummelkamp et a l, 2002). 
Some studies on siRNA silencing of oncogenes include not only decreases in 
mRNA and protein levels, but also suppression of monolayer and anchorage- 
independent growth, and even a decrease in tumour size in mouse models
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(Calvo et al., 2006; Yoshinouchi et al., 2003). New research techniques 
include the sensitization of cancerous cell lines to chemotherapeutic drugs with 
the use of siRNA against a target oncogene. Silencing the BCR-ABL 
oncogene was reported to increase sensitivity of leukaemia cells to imatinib 
(Glivec) and radiation (Wohlbold et al., 2003), while RNAi against HPV 
oncogenes in cervical cancer cells resulted in increased sensitivity to cisplatin 
(Putral et al., 2005). Clearly the utilization of siRNA as a therapeutic tool has 
vast implications for the treatment of a wide range of diseases; however, the 
need for development of efficient delivery systems is essential.
Although using siRNA in mammalian systems is of great use in studying the 
functions of genes and for understanding the genetic basis of cellular 
physiology, the molecular make-up of siRNA can make the conveyance 
difficult in vivo. There are two main factors that cause siRNA to be difficult to 
deliver in vivo. First, the physicochemical properties of siRNA, such as the 
large polar surface area and molecular size, make for poor intrinsic membrane 
permeability. Pre-clinical methods which have somewhat enhanced delivery 
involves the hydrodynamic intravenous injection of naked siRNA or shRNA 
(McCaffrey et a l, 2002). This technique involves injecting a large volume of 
siRNA solution over a short period of time. While this method had been 
successful in mouse models, delivery is still a problem in clinical applications 
as hydrodynamic intra venous infusion cannot be applied to humans in a safe 
manner.
The second factor in efficient RNAi delivery is that siRNA is rapidly degraded 
by both extracellular and intracellular nucleases. Chemical modifications can
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often increase stability, which increases the overall cellular uptake of siRNA 
(Soutschek et a l, 2004). Other vehicles, such as chemically unmodified 
siRNAs bound to polymers or liposomes have shown promise (Urban-Klein et 
a l, 2005; Yano et a l, 2004). One effective partnership is the complex formed 
by the binding of siRNA with polyethylenimines (PEIs), synthetic linear or 
branched polymers which contain characteristics that allow them to form non- 
covalent complexes with DNA and siRNA (Boussif et a l, 1995; Urban-Klein 
et a l, 2005). The formation of complexes with PEI leads to stable and 
uniformly sized particles that completely cover the siRNA, protecting the 
siRNA from the presence of RNAse {in vitro) and serum nucleases {in vivo) 
(Grezelinski et a l, 2006). Injection of PEI/siRNA into peritoneal or 
subcutaneous tissue of mice delivered intact radiolabled siRNAs into several 
organs, but not the blood (Urban-Klein et a l, 2005). The complexation of 
siRNAs with other molecules is a potentially powerful tool to achieve maximal 
function in vivo.
3.1.6 Summary
As Brfl (through TFIIIB) has been shown to be a target for many significant 
proteins involved in regulating levels of pol III transcription, and pol III 
transcription is linked to a cells biosynthetic capacity, one could expect that 
decreasing the levels of Brfl by siRNA might have an impact on a celTs 
phenotype. By using siRNA as a tool to decrease levels of Brfl, and hence pol 
III transcription, effects on intracellular characteristics such as mRNA and 
protein expression were observed, as well as phenotypic traits, including 
proliferation.
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3.2 Results
3.2.1 siRNA designed to target Brfl decreases pol III 
transcription in mammalian cells
siRNA designed to target Brfl was applied to cervical cancer cells by 
electroporation in order to assess the consequences of decreasing TFIIIB- 
subunit Brfl on pol III transcription. An effect on pol III transcription was 
observed after 48 hours, as seen by a decrease in pol III transcripts tRNA^^" 
and 5SrRNA, when compared to Lamin A/C control siRNA (Figure 3.3A). 
Decreases in pol III transcripts that use a type III promoter (i.e. U6 snRNA, 
7SK, tRNA^ '^ )^ are not seen, as this type of promoter does not utilize Brfl 
during transcription (see Introduction 1.5.3). Although Brfl siRNA 1 appears 
to decrease Brfl mRNA more efficiently than Brfl siRNA2, levels of tRNA^^“ 
do not reflect this as it would be expected that tRNA^®“ levels in cells treated 
with Brfl siRNA 1 would be more decreased than tRNA^^" levels in siRNA2. 
The reasons for this are unidentified and considered an anomaly.
Translational effects were observed as a decrease in Brfl protein levels was 
recorded after Western blotting when normalized to actin, a protein found in 
the cell cytoskeleton (Figure 3.3B). Brfl protein levels in lane 4 (siRNA-1) 
appear lower than those of lane 5 (siRNA-2), reflecting Brfl mRNA levels. As 
Brfl serves to recruit TFIIIB through interactions with pol III and TFIIIC, 
reducing Brfl levels probably hinders the binding of TFIIIB to the promoter, 
disrupting transcription.
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Figure 3.3 Small interfering RNA targeting Brfl reduces pol III 
transcription in vivo
A. Exponentially growing HeLa cells were electroporated with scrambled 
control siRNA (lane 1), Lamin A/C siRNA (lane 2), Brfl siRNA-1 (lane 3) and 
another Brfl siRNA-2 (lane 4) targeting a different region to Brfl siRNA-1. 
All siRNAs were transfected using 3 ug siRNA into each electroporation. Cells 
were harvested for RNA extracts 48 hours after transfection. RT-PCR analysis 
was then performed. Brfl (panel one), tRNA^" (panel two), 58 rRNA (panel 
three), U6 snRNA (panel four), tRNA ^ (panel 5), 7SK (panel 6), Lamin A/C 
(panel 7) and ARPP PO (panel 8) primers were used. Results are representative 
of three independent experiments. B. Protein extracts were harvested at 48 
hours after transfection, as above. Whole cell extracts were made and subjected 
to SDS-PAGE analysis and were immunoblotted with antibodies against Brfl 
(SK-2839, upper panel), or actin (lower panel). PC-B (panel 1) is a fraction 
containing TFIIIB and pol III, used as a marker.
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Daley et al. found Brfl to be a limiting factor for pol III transcription in 
cervical cells when increased concentrations of Brfl were found to stimulate 
tRNA^^“ and 5S rRNA transcription (2005).
Clearly, decreasing levels of Brfl by using siRNA would have an opposite 
effect. Because siRNA targeting Brfl decreased pol III transcription, we 
thought it would be interesting to see if this had any effects on the proliferation 
rate. Deregulation of pol III is a general characteristic of transformed cells 
(reviwed in White, 2004), so discovering if decreasing pol III transcription 
through Brfl siRNA in transformed cells would be sufficient to decrease 
proliferation would be beneficial.
3.2.2 Brfl siRNA decreases the proliferation rates of two types 
of transformed mammalian cells
To access the proliferation rates of both cervical carcinoma cells (HeLa) and a 
breast adenocarcinoma cell line (MCF-7), cells were electroporated with Brfl 
siRNA, harvested and counted at 0 and 72 hours. Proliferation rates of HeLa 
cells treated with two different Brfl siRNAs, as well as a pool of these two 
siRNAs showed a ~2 fold decrease in proliferation rates at 72 hours when 
compared to cells treated with control siRNA at 72 hours (Figure 3.4).
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Figure 3.4 Transfection of HeLa cells with Brfl siRNA decreases the 
proliferation rate in HeLa cells
Cells were electroporated with either 3 ug siRNA targeting Lamin A/C (blue 
bars), Brfl (green and purple bars) or a pool of siRNA targeting Brfl (light 
blue bars). siRNA-1 and siRNA-2 reflect two separate siRNAs targeting 
different regions of mRNA within Brfl. The Brfl siRNA pool represents a 
mixture o f siRNA-1 and siRNA-2 to equal 3 ug total. Cells were counted at 
0 and 72 hours. Results are representative of three separate experiments. 
Mean percentage change of all Brfl siRNAs is 59.8%. Standard deviations 
(in percentages) are as follows; Lamin A/C time 0, 10.3; Lamin A/C time 
72, 66.0; Brfl siRNA-1 time 0, 6.8; Brfl siRNA-2 time 72, 51.8; Brfl 
siRNA-2 time 0, 3.3; Brfl siRNA-2 time 72, 46.4; Brfl siRNA pool time 0, 
11.1; Brfl siRNA pool time 72, 18.5./?= 0.0014
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To verify the siRNA v^as functioning, pol III transcripts, as well as Brfl 
mRNA and proteins levels were checked. Indeed, at 72 hours cells treated 
with Brfl siRNA were found to have decreased levels of Brfl mRNA and 
protein, and levels of pol III transcripts tRNA^^" and 5S rRNA were also 
decreased when compared to control Lamin A/C mRNA (Figure 3.5A, 3.5B). 
Levels of Lamin A/C mRNA increased slightly from 0 to 72 hours, possibly 
due to non-specific effects. However, because mRNA levels are normalized to 
the pol II transcript ARPP PO, comparisons between mRNA levels from Brfl 
siRNA and Lamin A/C siRNA treated cells can still occur.
Brfl siRNA-2 decreased Brfl mRNA levels less efficiently than Brfl siRNA- 
1 ; however, these two siRNAs, as well as the Brfl siRNA pool, give equally 
potent anti-proliferative effects. Perhaps this can be explained by the idea that 
the siRNA system may be saturable. Even though the same concentration of 
Brfl siRNA was used, the system may be saturated by the least effective 
siRNA used (Brfl siRNA-2). Therefore, any siRNA that decreases Brfl levels 
beyond this point may not affect proliferation rates if proliferation is not 
affected by the further decrease in Brfl mRNA levels. If this saturable amount 
of Brfl is achieved by Brfl siRNA-2, than all other Brfl siRNAs would have 
the same affect on proliferation.
Cell death was eounted by staining with trypan blue to check that the decrease 
in proliferation rate was not due an increase in cell death, but rates were too 
low to be significant and the same in all samples.
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Figure 3.5 RT-PCR and Western blotting results correlate with 
decreases in proliferation rates in Brfl siRNA transfected HeLa 
cells
A. Cells were electroporated with siRNA as above, in Figure 3.4. 
After cells were counted RNA extracts and whole cell extracts (B, 
below) were made. PCR was carried out using primers for Brfl (panel 
one), tRNA^^" (panel 2), 5S rRNA (panel 3) and ARPP PO (panel 4). 
These results are indicative of two independent experiments.
B. Cell extracts were subjected to SDS-PAGE analysis and Western 
blotting was applied. An antibody against Brfl (SK-2839, upper panel), 
or actin (lower panel) was used for immunoblotting. These results 
represent two separate experiments.
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The proliferation rates of MCF-7 eells after treatment with Brfl siRNA were 
also assessed. MCF-7 cells treated with two different Brfl siRNAs, as well as 
a pool of these two siRNAs, showed a -1.5 fold decrease in proliferation rates 
at 72 hours when compared to cells treated with control siRNA at 72 hours 
(Figure 3.6).
Error was higher in the MCF-7 proliferation chart as cells were more difficult 
to work with, as they needed to be plated at a high density for growth. By the 
end of 72 hours these cells grew out of a monolayer, making them hard to 
remove from the culture dish. mRNA and protein levels were not assessed as 
the RNA and protein extracted from these cells was insufficient to perform 
adequate analysis. Trypan blue staining and subsequent counting for cell death 
was also performed, results paralleling that of the HeLa cell line.
The coinciding results of these two experiments show the parallel affects of 
decreasing Brfl levels in two different transformed cell lines. The question 
remains as to how decreasing Brfl directly affects the proliferation rate of a 
cell, which will be discussed below.
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Figure 3.6 Brfl siRNA decreases proliferation rates in MCF-7 cells
Cells were harvested at 72 hours after electrporation with 3 pg Lamin A/C 
siRNA (purple), Brfl siRNA-1 (ivory), Brfl siRNA-2 (dark purple) or Brfl 
siRNA pool (light blue). Brfl siRNA-1 and Brfl siRNA-2 represent two 
different siRNAs targeting different regions of Brfl. Brfl siRNA pool 
represents a pool of these two siRNAs, totaling 3 pg. These results are from 
two independent experiments.
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3.3 Discussion
The untranslated RNAs produced by pols I and III are primarily involved in
cellular biosynthesis, the major determinant in the rate of cell growth and
division. If a cell increases its rate of protein synthesis, proteins accumulate to
a point of sufficient protein mass, and a cell divides (Baxter and Stanners,
1978). In this way, cell growth is rate-limiting for cell division (Johnston et
a l, 1977). As the availability of pol III transcripts tRNA and 5S rRNA are a
major factor of protein synthetic capacity, high rates of pol III transcription are
essential for rapid growth. This rapid growth is a characteristic of transformed
cells. Thus, pol III products are generally found to be overexpressed in
transformed and tumour cells, and these results show that both HeLa and
MCF-7 cells have increased amounts of pol III products compared with normal
cells (Chen et a l, 1997; Felton-Edkins and White, 2002). When Brfl siRNA
decreases the amount of Brfl bound into TFIIIB complexes, less TFIIIB is
available to recruit pol III and position it at the start site. Hence, there is a
decrease in transcription from type I and II promoters, the products of which
are extremely influential upon cellular growth and proliferation. This
characteristic becomes significant when increased levels of pol III transcripts
in transformed cells can be decreased by techniques such as siRNA, bringing
the cells back to a more “normal” physiological state. This research provides
evidence of a direct link between the levels of Brfl in a cell and its ability to
influence cell division. Further research might include an experiment such as
measuring protein synthesis, and FACS analysis. Cells treated with siRNA
targeting Brfl would probably decrease their protein turnover rate. This could
be tested by monitoring incorporation of [^^S]-Met in a pulse-chase
experiment. FACS analysis would provide an insight into the progression of
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these cells through the cell cycle, and how cells treated with control siRNA 
differed from those treated with Brfl siRNA.
A more extensive panel of controls could also be applied. Mismatched or 
scrambled Brfl siRNA could be used, although a rescue experiment would be 
the most conclusive. A siRNA vector-based inducible system could be made 
and used to decrease expression of the Brfl gene. The inducible system could 
then be shut off, and proliferation rates could be analyzed to discover if they 
returned to higher levels once Brfl levels increased. Titrations of siRNA could 
also be carried out, to observe the optimal siRNA concentration and to 
minimize non-specific effects.
Although using Brfl siRNA to decrease pol III transcription was successful, 
we decided to use other techniques to directly target pol III transcription. 
Using siRNA is effective once the system is optimized, but this technique can 
be laborious and therefore other systems might provide added benefits. The 
following chapters discuss the targeting of pol III transcription through two 
different techniques; one through direct application of the drug tagetitoxin, and 
the other through a recently discovered pol III negative effector Maf 1.
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Targeting RNA polymerase III with tagetitoxin 
decreases transcription in mammalian cells
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4.1 Introduction
4.1.1 Tagetitoxin: the discovery of a RNA polymerase III 
inhibitor
Tagetitoxin, a bacterial phytotoxin, is produced in liquid cultures of the plant 
pathogenic bacterium Pseudomonas syringae pv. tagetis (Mitchell and Durbin, 
1981). This substance was found to causes chlorosis, a condition in which 
plant foliage produces insufficient chlorophyll in developing, but not mature, 
plant leaves (Trimboli et a l, 1978). The levels of chloroplast ribosomal RNA, 
as well as mRNAs, are severely reduced in the leaves of tagetitoxin-treated 
seedlings (Lukens et a l, 1987). This led researchers to investigate the 
mechanism of action of tagetitoxin on chloroplast metabolism. Indeed, 
tagetitoxin turned out to be a selective inhibitor of chloroplast RNA 
polymerase, providing an explanation for the reduced chloroplast ribosomal 
levels, the decreased mRNA levels, and chlorosis all observed in tagetitoxin- 
treated plants (Mathews and Durbin, 1990). Further studies still included 
tagetitoxin research in plants, but also broadened to encompass other species.
In 1990, Mathews and Durbin provided the first evidence that in vitro RNA 
synthesis directed by the RNA polymerase from Escherichia coU is inhibited 
by tagetitoxin (Mathews and Durbin, 1990). In vitro transcription by RNA 
polymerase II, isolated from wheat germ, had an extremely decreased 
sensitivity to the toxin and SP6  and T7 RNA polymerases from bacteriophages 
were unaffected by tagetitoxin at high concentrations. In the same year, a 
partnership with a another research group demonstrated the ability of 
tagetitoxin to preferentially inhibit eukaryotic pol III (Steinberg et a l, 1990).
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The results in this study further characterised the action of tagetitoxin, as pol 
III transcription directed from HeLa, Xenopus laevis (African clawed frog), 
Bombyx mori (silkwoim). Drosophila melanogaster (fruitfly) and 
Saccharomyces cerevisaie extracts was inhibited. Tagetitoxin did not inhibit 
transcription from calf thymus pol II, reinforcing this group’s previous findings 
and establishing a control for tagetitoxin testing (Mathews and Durbin, 1990; 
Steinberg et a l, 1990). Understanding the mechanism of action of tagetitoxin 
began with this research. The inhibition of silkworm pol III seemed to act 
directly on the polymerase, rather than by binding a transcription factor 
(Steinberg et a l, 1990).
4.1.2 The mechanism of tagetitoxin: enhanced pausing at 
discrete sites
Studies were performed in yeast extracts to further determine the mechanism 
of action of tagetitoxin. Due to the lengthy purification procedures necessary 
to obtain tagetitoxin from P. syringae pv. tagetis, the following studies 
switched to a commercially available partially purified form of tagetitoxin, 
with the trade name Tagetin'’’!^  (Epicentre® Technologies). Tagetin^M was 
found to contain the same activity as the previously used tagetitoxin (Steinberg 
etal ,  1990).
Steinburg and Burgess treated yeast extracts with tagetitoxin and performed in-
vitro transcription experiments on a tRNA gene, adding varying concentrations
of nucleotides (1992). Tagetitoxin inhibition of transcription was more
pronounced at low nucleotide levels and ereated tagetitoxin-enhanced small
RNAs, in addition to primary unprocessed pre-tRNA transcripts. These small
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and lower molecular weight RNAs result from transcription complex pausing, 
premature termination, or processing of the full-length transcript. These data 
showed that the inhibitory effeet of tagetitoxin depends, to some degree, on 
total nucleotide concentration.
To further elucidate the way in which tagetitoxin inhibits pol III transcription, 
for example, if the short RNAs mentioned above were formed because of the 
accumulation of stalled complexes or RNA release, multiple round 
transcription of the tRNA^®“ gene in yeast extract was done at a high 
concentration of tagetitoxin (Steinberg and Burgess, 1992). After 5 minutes 
the transcription reaction was stopped, fractions collected, and then portions of 
these fractions were added to nucleotides and MgCb. Small RNAs created by 
tagetitoxin treatment and corresponding to the low molecular weight RNAs in 
the previous experiment are contained in the ternary complex which contains 
DNA, pol III, and growing RNA chains that migrate distinctly from and ahead 
of the full-length precursor tRNA. These small RNAs also migrated separately 
from other small RNAs that result from premature termination and release or 
processing of the mature transcript. Therefore, these low molecular weight 
RNAs created from tagetitoxin treatment are created by pausing of the 
transcription complex, not from RNA release. Further experiments implicated 
the interference of tagetitoxin with nascent RNA chain elongation (Steinberg 
and Burgess, 1992). Together, this research suggests that the primary effect of 
tagetitoxin is increased stability of intrinsic pausing, depending on the 
frequency and stability of pausing by pol III.
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4.1.3 The structure of tagetitoxin
Work focusing on revealing the structure of tagetitoxin began soon after it was 
reported to be a specific inhibitor of pol III. Early work suggested that 
tagetitoxin has a molecular weight (MW) of 435, held the molecular formula of 
CiiHisOiaSNP, and was a highly unusual and novel molecule (Mitchell and 
Hart, 1983). Later, more intricate studies deduced the inhibitor to consist of 
two fused 6 -membered heterocyclin rings with the molecular formula revised 
to C11H 17N2 O11PS with a MW of 417 (Mitchell et a l, 1989) (Figure 4.1).
Most of the work done to further characterize the structure has been done in 
order to chemically modify the inhibitor for use as a plant growth regulator and 
as an herbicide (Dent et a l, 1999). Recent work on the structural basis for 
transcription inhibition by tagetitoxin found that tagetitoxin inhibited all 
catalytic activities of Thermus theromophilus RNA polymerase (RNAP) by 
“freezing” the RNAP catalytic centre in an inactive state (Vassylyev et a l, 
2005). Mg^  ^may have a role in the stabilization of an inactive transcription 
intermediate, remodelling the site of active transcription. Additional analysis 
of the structure of tagetitoxin, along with mechanistic investigations, are 
needed to clarify the function of this inhibitor on pol III.
As tagetitoxin was found to be a specific inhibitor of pol III transcription in 
vitro, the aim of my experiments with the commercially available compound, 
Tagetin™, was to analyse the effectiveness of tagetitoxin when applied to 
mammalian cells in vivo.
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tagetitoxin
Figure 4.1 The structure of tagetitoxin (Mitchell et al., 1989)
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4.2 Results
4.2.1 Tagetitoxin does not serve as a specific pol III inhibitor in 
vivo when directly applied to mammalian cells
To test whether Tagetin^M could inhibit pol III transcription in a mammalian 
system by transfection, 45 micromoles (pM) of tagetitoxin was added per well 
to NIH 3T3 cells for 2 hours. Cells were then harvested for RNA and cDNAs 
were created for RT-PCR analysis. Only the B2 pol III transcript appeared 
decreased, and all other transcripts, tRNA^™, 5S rRNA, and 7SK increased 
when compared to the pol II control ARPP PO (Figure 4.2A). This experiment 
was performed three times to verify these results. Tagetin™ was active, as in 
vitro transcription reactions showed a decrease in pol III transcripts when the 
drug was added (Figure 4.2B). Perhaps B2, found only in mouse cell lines, is 
more sensitive to tagetitoxin than the other pol III transcripts or this could be 
some sort of artefact from the treatment of cells with a drug. Allen et al. used 
tagetitoxin to do studies on SINE-encoded mouse B2 RNA and heat shock, and 
one RT-PCR analysis shows a decrease in B2 RNA levels without heat shock, 
and no effect on 7SK RNA (2004). tRNA^^" and 5S rRNA were not analysed. 
The results of my studies seem to mimic those of this experiment, although the 
reason for the increases in tRNA’^®“ and 5S rRNA still remains unexplained. 
Contact was made via e-mail to this laboratory, but they reported that there 
were no attempts at analysing other pol III transcripts. Whatever the case, no 
previous research has reported the use of tagetitoxin in vivo by direct 
application into culture medium, but the ease of use and specific activity on pol 
III prompted us to attempt it.
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B2
tRNA^G"
U6 snRNA
7SK
ARPP PO
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5S rRNA ------ ►
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5SrRNA -------►
tRNA^eu -------- ^
VAl -------►
pol I ------ ►
1 2
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Figure 4.2 Tagetitoxin does not decrease pol III transcription (in 
NIH 3T3 cells) when applied to culture medium
A. After cells were seeded in 6 -well culture plates they were left at 
normal culture conditions for 24 hours before no treatment with (lane 1) 
or treatment with 45 \xM Tagetin'*’’^  (lane 2). After 2 hours incubation 
cells were harvested for RNA. RT-PCR analysis was then performed 
using primers for B2 (panel 1), tRNA^^" (panel 2), 5S rRNA (panel 3), U 6  
snRNA (panel 4), 7SK (panel 5) and ARPP PO (panel 6 ). These results 
are representative of three separate experiments.
B. An in vitro transcription assay was done to confirm the activity of the 
drug Tagetin'T^. HeLa nuclear extracts were incubated with no Tagetin^^ï 
(lane 1) or treatment with Tagetin™ (lane 2) for 10 minutes prior to 
incubation with a reaction mixture including [a-^^P] UTP, etc. and DNA 
templates 5S rRNA (panel 1), tRNA^®” (panel 2), or VAl (panel 3). A pol 
I rRNA primer is used as a control. After a reaction time of 60 minutes 
the reaction was stopped, protein and DNA was removed and the RNA 
was extracted. Formamide loading buffer was added, vortexed and then 
run on a polyacrylamide sequencing gel. These results are representative 
of two independent experiments.
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4.2.2 Treating NIH 3T3 cells after heat shock with tagetitoxin 
decreases pol III transcription
As experiments demonstrated by Kugel’s group with tagetitoxin and heat 
shock were successful at inhibiting pol III transcription (in select transcripts), 
in vivo attempts were made to duplicate these experiments within our 
laboratory (Allen et a l, 2004). NIH 3T3 cells were treated with tagetitoxin for 
60 minutes, heat-shocked for 25 minutes at 45°C, and allowed to recover for 
25 minutes before RNA extracts were made. RNA levels were evaluated by 
RT-PCR. tRNA^^" and 5S rRNA were detected when cells were heat shocked 
without tagetitoxin treatment, but after application levels of tRNA^®“ were not 
detectable and 5S rRNA levels were decreased when compared to the control 
(Figure 4.3). Levels of B2 appear to be increased (lane 2), which may reflect 
B2’s response to heat shock and the combined non-specific effect drug 
treatment. This will be discussed further, below.
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Figure 4.3 Treating NIH 3T3 cells after heat shock with 
tagetitoxin decreases pol III transcription
NIH 3T3 cells were seeded into a 6-well culture plate. After 
24 hours of normal culture conditions cells were either given 
no treatment (lane 1) or treated with 45 pM Tagetin™ (lane 
2) and incubated for 60 minutes at 37°C. Cells were then 
heat shocked for 25 minutes at 45°C, and then allowed to 
recover for 25 minutes at 37°C before harvested for RNA. 
RT-PCR analysis was carried out with primers for B2 (panel 
1), tRNA^®“ (panel 2), 58 rRNA (panel 3), 7SK (panel 4) and 
ARPP PO (panel 5). These results are representative of two 
independent experiments.
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4.2.3 Electroporation of HeLa cells with tagetitoxin decreases 
pol HI transcription
Electroporation is a significant increase in the electrical conductivity and 
permeability of the cell plasma membrane caused by an externally applied 
electrical field. In molecular biology it is used as a way of introducing a 
substance into a cell, such as DNA or a drug. When voltage is applied, pores 
are formed across a plasma membrane, the substance enters the membrane, and 
when electroporation ceases the pores reseal, allowing the substance to move 
across the membrane into the cell.
One additional method was attempted to introduce Tagetin™ into mammalian
cells. HeLa cells were used in this experiment as it was demonstrated in Wang
et ah that tagetitoxin decreased pol III transcription after microinjection in
HeLa cells (2003). In addition, greater quantities of RNA are able to be
harvested from HeLa cells compared to NIH 3T3, and this trait was
advantageous when harvesting these cells after nucleofection. HeLa cells were
electroporated with an Amaxa (Amaxa Biosystems) nucleofector during
simultaneous treatment with 45 pM tagetitoxin. After 48 hours, cells were
harvested for RNA and cDNAs were created for RT-PCR analysis. Pol III
transcripts tRNA^^" and SSrRNA were greatly reduced, while 7SK was slightly
reduced, but not the pol II control, indicating specific targeting of pol III
(Figure 4.4). The reason for a slightly decreased level of 7SK is debatable, as
previous data differed, showing no change in 7SK mRNA levels in NIH 3T3
cells when treated with tagetitoxin (Allen et a l, 2004). However, tagetitoxin
inhibition of pol III transcription can be template- dependent, and 7SK uses the
unusual pol III type III promoter structure, unlike those of tRNA and 5s rRNA
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genes. Studies on the yeast U6 snRNA gene found that about 3-fold more 
tagetitoxin was required to give half-maximal inhibition of transcription when 
compared to the tRNA gene, suggesting that the gene template might change 
the effectiveness of tagetitoxin (Steinberg and Burgess, 1992). 7SK uses the 
same promoter type as U6 snRNA, and therefore perhaps 7SK RNA levels are 
influenced differently than those genes transcribed from type I (5S rRNA) and 
type II (tRNA) promoters.
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Figure 4.4 Electroporation of HeLa cells with 
tagetitoxin decreases pol III transcription
HeLa cells were transfected by electroporation 
(Nucleofector, Amaxa) with either dHjO or 45 pM 
TagetinTM and harvested for RNA 48 hours later. RT- 
PCR analysis was carried out using primers for pol III 
templates tRNA^®“ (panel 1), 5S rRNA (panel 2), 7SK 
(panel 3) and pol II control template ARPP PO (panel 4). 
These results are representative of three independent 
experiments.
106
Chapter 4
4.3 Discussion
It is apparent that the direct application of tagetitoxin to cells via culture 
medium does not decrease pol III transcription (Figure 4.2). This follows the 
current unpublished research on the inability of tagetitoxin to cross the cell 
membrane without assistance. When contact was made with Epicentre® 
personnel via telephone they could not report a successful attempt at inhibiting 
pol III transcription by the direct application of Tagetin™ to mammalian cells 
in vivo, and they did not recommend it. Introduction of tagetitoxin into HeLa 
cells by microinjection has been successful, although this technique is not 
feasible within our laboratory (Wang et a l, 2003). This impelled us to find 
other ways to introduce tagetitoxin into mammalian cells.
The significance of the heat shock results, however, is undetermined. Time 
permiting, another control would have been beneficial; such as no treatment 
and no heat shock. Without this control it is hard to conclude if the decrease in 
the treated and heat-shocked cells are firom the tagetitoxin or merely appear to 
be decreased compared to increased transcripts from heat shock treatment 
(such as in Figure 2, Allen et a l, 2004). A no heat shock, no Tagetin'^^ control 
would control for effects from heat shock, allowing for comparisons between 
this control and the heat shock and Tagetin™- treated cells. If levels of pol III 
transcripts compared to this control were decreased, compared to the non­
treated control, then perhaps deductions could be made as to the performance 
of tagetitoxin. Indeed, it might suggest that the tagetitoxin was able to gain 
entry into the cell via a mechanism induced by heat shock. Human heat shock 
proteins (hsps) have been found to induce ion conducting pores across lipid
bilayers, however there are no reports of drugs being introduced into a cell
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through heat shock (Alder et a l, 1990). This method was not used for further 
studies as the widespread effects of heat shock on mRNA transcription are not 
currently known.
Another way to perceive the heat shock results is that the application of 
tagetitoxin by heat shock did not allow the drug to cross the membrane, but 
that this was a non-specific response to the drug treatment. Allen et al 
published that transcription of B2 mRNA increases rapidly after heat shock 
treatment, but this increase is blocked when cells are treated with both heat 
shock and tagetitoxin (2004). The experiment shown in Figure 4.3, above, 
does not parallel this result. Perhaps the effects of both heat shock and 
tagetitoxin on B2 mRNA levels causes a heightened heat shock response, and 
the decreases in the remaining pol III transcripts is an anomaly. Allen et al. 
also demonstrated the inhibition of B2 RNA on pol II transcription. mRNA 
levels in Figure 4.3 were normalized to levels of the pol II transcript, ARPP 
PO, and normalizing to this transcript may have affected the results.
Treating cells with tagetitoxin during electroporation seems to provide a new 
tool for the introduction of drugs into HeLa cells, although the effects of 
electroporation itself have not been taken into consideration. It would be 
interesting to discover if other drugs could be introduced this way into cells, 
and if the cells are affected by nucleofection. Another method would be to try 
transfection of tagetitoxin by the addition of calcium phosphate, a method 
widely used in the transfer of genetic material and viruses into cells; however, I 
was unable to find any reports stating the useage of calcium phosphate in the 
application of drugs in cell culture condition. In any case, electroporation,
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above all others mentioned within this chapter, could be fine-tuned and utilized 
for further studies on the effects of decreasing pol III transcription in 
mammalian cells.
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Induction, silencing and deletion o f  M afl 
affects RNA polym erase III transcription in
mammalian cells
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5.1 Introduction
5.1.1 Discovery of M afl, a new pol III repressor
In 1997 a new gene, MAPI, was Identified in a yeast screen for mutations 
affecting the efficiency of action of a nonsense suppressor tRNA (Boguta et 
al, 1997). Mutations in this 395 amino acid nuclear protein showed two 
phenotypic effects: antisuppression and temperature sensitivity in respiratory 
growth (Boguta et a l, 1997; Pluta et al, 2001). These links to both tRNA 
suppression and growth lead researchers to screen a multicopy gene library for 
complementation of the temperature sensitive mutant phenotype mafl-l. 
Overexpression of RPC 160, a gene which encodes the largest subunit of RNA 
polymerase III, suppressed the above phenotypes, demonstrating a genetic link 
between pol III and Mafl. It is this research that spawned additional 
biochemical analysis to identify the primary function of the MAPI gene 
product.
Further studies continued to define Mafl as a negative effector of pol III. 
Mutations in RPC 160 were shown to mimic the above-mentioned phenotypes, 
providing more evidence linking pol III and Mafl physically (Pluta et a l,
2001). Co-immunoprecipitations between HA-tagged RPC 160 and myc- 
tagged Mafl suggested a direct interaction between Mafl and pol III. 
Additional evidence suggested a role for Mafl in the tRNA biosynthetic 
pathway, Mafl potentially regulating the level of cellular tRNA in response to 
external signals (Pluta et a l, 2001). After these initial experiments, studies 
began to focus on the role of Mafl in pol Ill’s response to nutrient limitation 
and the mechanism in which Mafl represses pol III transcription.
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5.1.2 M afl, a common component of multiple signalling 
pathways
The transcription of pol I and III genes is tightly coupled with nutrient 
availability and is affected by a wide variety of treatments and conditions 
including; drugs, secretory pathway defects and DNA damage that disturb the 
cellular environment (Ghavidel and Schultz, 2001; Stenfanovsky et a l, 2001). 
The disruptions caused by nutrient limitation and treatments/conditions are 
detected by unique signalling pathways that converge on the transcription 
apparatus, affecting regulation. Recently, it was shown that Mafl is a common 
component of these signalling pathways, providing a critical link between 
these diverse pathways and the pol III transcription machinery (Upadhya et a l,
2002) (summarised in Figure 5.1).
5.1.2.1 The secretory pathway
Initial experiments on yeast were performed to determine the manner in which 
Mafl was affecting pol III transcription. By deleting MAPI in a ypt6-l S. 
cerevesiae strain and subjecting the yeast to nonpermissive temperatures to 
inactivate the secretory pathway, researchers found that the control strain 
repressed tRNA transcription, while in the ypt6-l mafl A strain repression of 
tRNA transcription was blocked (Li et a l, 2000; Upadhya et a l, 2002). These 
results were an indication that Mafl is essential for the repression on pol III 
transcription following inactivation of the secretoiy pathway.
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Secretory Nutrient DNA damage
pathway defect limitation e.g. UV/MMS
Wsc proteins TOR kinases
CD
V
Mafl
M ed /T e ll
Pol III transcription
Figure 5.1 M afl is a convergent point for regulation of pol III by 
multiple signaling pathways (adapted from Upadhya et a i ,  2002).
Conditions that repress pol III transcription are shown in boxes, near 
top. Proceeding each arrow is the upstream sensor or transducers that 
distinguish each signaling pathway. The dashed effect o f the blue 
arrows indicate that there are still unknown elements o f these pathways, 
the point(s) o f convergence not yet known. Arrows symbolize 
activation o f signaling and bars indicate repression.
13
Chapter 5
To ascertain which proteins within the secretory pathway might be influencing 
Mafl repression of pol III, cells were treated with tunicamycin, a drug which 
inhibits protein N-glycosylation in the endoplasmic reticulum and which 
requires proteins within the Wsc family (LI et a l, 2000). Wsc proteins are 
found along the secretory pathway and in the plasma membrane, initiating 
signaling by sensing stressful conditions within the cell. Treatment of cells 
with tunicamycin reduced transcription of pol III genes in the wild-type strain, 
however, this repression was abolished in the mafl à. (as above) strain 
(Upadhya et a l, 2002). This provided more definitive evidence that Mafl is a 
mediator in the secretory pathway.
5.1.2.2 Nutrient limitation
Another characteristic of Mafl is its ability to respond to nutrient limitation 
with repression of pol III transcription (Upadhya et a l , 2002). Rapamycin, a 
macrolide antibiotic which inhibits the conserved target of rapamycin (TOR) 
kinases, can be used to induce the effect of nutrient limitation on transcription, 
mimicking the nutrient starvation phenotype (Barbet et a l, 1996; Rohde et a l, 
2001). TOR kinases are a very important set of proteins within the cell, 
beginning a signaling cascade that starts when decreases in nutrients are 
sensed, and ending with changes in cell growth and proliferation (Schmelzle 
and Hall, 2000). Inhibition of TOR results in the rapid repression of tRNAs 
and rRNA genes transcribed by pol I and pol III (as well as some pol II genes), 
altering ribosome biogenesis (Cardenas et a l, 1999). Temperature studies 
using yeast with a mutation in the TOR pathway provide further evidence of a 
direct connection between the TOR pathway and pol III transcription 
(Zaragoza et a l, 1998). Experiments performed by Upadya et al
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demonstrated that it was Mafl which was receiving a signal from the TOR 
kinase pathway, in turn repressing pol III transcription (2002).
5.1.2.3 DNA damage
Mafl has a role in yet another signaling pathway- the DNA damage pathway, 
probably through checkpoint protein kinases M ed and Tell (ATM and ATR, 
respectively, in humans) (reviewed in Nyberg et al, 2002). The DNA damage 
surveillance system has a series of checkpoints that are responsible for genome 
integrity through proper detection and repair of DNA damage caused by 
environmental stresses or irregularities during DNA metabolism. M ed and 
Tell function by regulating an important group of proteins that detect, signal 
and repair DNA damage (Rouse and Jackson, 2002). Not all components of 
this pathway have been identified, and the precise manner in which M ed and 
Tell signal pol III repression through Mafl remains elusive.
Although the exact mechanisms by which Mafl is signalled by the multiple 
pathways above are currently not known, research regarding how Mafl affects 
the pol III transcription apparatus has provided enlightenment to the 
downstream effects of these various pathways.
5.1.3 M ars mechanism of action
Initial work on the way in which Mafl functions to repress pol III transcription 
was performed in yeast, although recent research in mammalian systems has 
provided analogous information. Studies involving the complex mechanism of 
action of Mafl on the pol III transcription apparatus have made headway
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recently, although some mysteries remain. Even so, M afl’s activity seems to 
be based around three main characteristics; nuclear localization, 
phosphoregulation, and direct targeting of TFIIIB subunit B rfl.
5.1.3.1 Mafl is a nuclear protein
Mafl was initially found within the nucleus when HA-tagged Mafl was 
detected by indirect immunofluorescence microscopy (Pluta et a l, 2001). 
Further studies in S. cerevisiae showed that Mafl is found in both the 
cytoplasm and the nucleus, although localization to the nucleus only occurs 
during nutrient starvation, growth to stationary phase, or with treatment by 
rapamycin (Roberts et a l, 2006). Under active growth conditions, Mafl is 
largely excluded from the nucleus, although residual amounts remain (Moir et 
al, 2006). This localization is required for transcriptional repression (Roberts 
et a l, 2006). Nuclear accumulation is regulated by a two nuclear localization 
sequences (NLSs) within the protein, one of these sequences (an N-terminal 
NTS, NtNLS) being functionally tied to the regulation of pol III by protein 
kinase A (FKA).
5.1.3.2 Mafl repression of pol III: a balance between PKA and protein 
phosphatase 2A (PP2A)
Mafl contains six consensus PKA phosphorylation sites, in addition to the two 
localization sites mentioned above. One of these sites, the NtNLS, overlaps 
two PKA sites. Recent studies by Moir et a l have shown that Mafl is 
phosphorylated by PKA at the NtNLS, and high phosphorylation activity 
blocks repression of pol III transcription (2006). Both NLS motifs were found
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to independently direct Mafl to the nucleus under normal conditions, however, 
the NtNLS activity is required for efficient relocation under repressing 
conditions and is regulated by PKA. Therefore, under conditions of active 
growth, Mafl is phosphorylated by PKA and mostly excluded from the 
nucleus. When growth-limiting conditions occur, Mafl is localized to the 
nucleus, suggesting that Mafl activity may require a PKA-independent 
activation step in order for nuclear Mafl to repress pol III transcription. This 
activation step was found to be performed by PP2A, functioning to 
dephosphorylate Mafl, Mafl then undergoing import to the nucleus 
(Oficjalska et a l, 2006). After Mafl is dephosphorylated by PP2A, Mafl can 
interact with pol IITs largest subunit. C l60, within the nucleus. Thus, the 
phosphorylation states of Mafl are kept in balance by PKA and PP2A, 
functioning to communicate the cells nutrient state to Mafl, which can then 
interact with the pol III apparatus to regulate transcription (see Figure 5.2).
There is one caveat to this, however. Recently, experiments with a mutant 
form of Mafl lacking all PKA sites has revealed an interesting discovery. The 
Mafl mutant protein is nuclear under all growth conditions, yet pol III 
transcriptional activity was not diminished (Moir et a l, 2006). Pol III 
transcription was only decreased after treatment with rapamycin. This 
suggests that there must be an additional factor/step involved in transforming 
Mafl to its repressive state, as dephosphorylation and nuclear accumulation 
alone are not sufficient for Mafl-mediated repression.
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Figure 5.2 Model of the functions of Mafl as negative regulator 
of RNA polymerase III (adapted from Geiduschek and Kassavetis, 
2006).
During normal growth in nutrient-rich media, Mafl is phosphorylated 
on consensus PKA sites and is found mostly within the cytoplasm. 
The NtNLS (triangle) and CtNLS (oval) direct the nuclear import of 
Mafl. Phosphoryation at consensus PKA sites represses nuclear 
import by the NtNLS. Many conditions lead to the dephosphorylation 
of Mafl which results in nuclear accumulation. The opposing actions 
of PKA and PP2 A in response to nutrients determines the regulation 
of Mafl localization. PKA is regulated by the RAS/cAMP pathway 
and PP2A by the TOR pathway. Because nuclear accumulation is not 
sufficient to repress pol III transcription, an additional unknown 
activation step (orange circle) might allow nuclear Mafl to effect 
inhibit pol III transcription. Mafl represses two separate steps of 
transcription: V) de novo assembly of TFIIIB by TFIIIC; and 2) the 
disruption of transcription from pre-assembled TFIIIB-DNA 
complexes. Two alternative mechanisms are proposed for inhibition 
of step two. Arrows symbolize activation of signaling, and bars 
indicate repression.
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5.1.4 Mafl associates with pol III and TFIIIB
5.1.4.1 Pol III
Studies in Saccharomyces cerevisiae were first to identify the interaction 
between both pol III and TFIIIB with Mafl (Desai et a l, 2005; Murawski et 
a l, 1994; Pluta et a l, 2001; Upadhya et a l, 2002). Genetic studies suggested 
an interaction between Mafl and pol III when elevated levels of tRNA, caused 
by decreased Mafl, was suppressed by alterations of pol III subunit C l60 
(Murawski et a l, 1994; Pluta et a l, 2001). Coimmunoprecipitation 
experiments proved this supposition when C l60 was found to bind to Mafl in 
vitro. Pluta et a l also reported a slight increase of TFIIIB (Brfl) signal in 
their Western blot above background, hinting at the possibility of a Brfl-Mafl 
interaction, although the data were not shown (2001). The least 
phosphorylated form of Mafl preferentially binds to pol III in both pol Ill- 
active and pol Ill-repressed cells. However, the interaction between Mafl and 
pol III in repressed-cell extracts is greater, which reinforces the hypothesis that 
Mafl is dephosphorylated and transferred to the nucleus upon repression 
(Oficjalska et a l, 2006; Roberts et a l, 2006).
5.1.4.2 TFIIIB
Research stemming from Ian Willis’s laboratory proved that Mafl interacts 
with TFIIIB, namely Brfl, and shortly thereafter provided evidence of direct 
binding using recombinant proteins (Desai et a l, 2005; Upadhya et a l, 2002). 
The discovery of TFIIIB-Mafl binding was significant, as TFIIIB is a major 
regulatory target for transcription by pol III, and this discovery provided 
insight into possible mechanisms in which Mafl could apply its transcriptional 
control.
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5.1.5 The mechanism of action of Mafl on the pol III 
transcription apparatus
5.1.5.1 Mafl inhibits two distinct steps in transcription
Mafl repression of pol III transcription occui's in two separate steps; one 
focusing on the inhibition of TFIIIB recruitment and the other on the inhibition 
of pol III function.
Inhibition of TFIIIB recruitment
Once Mafl was established as a common component of multiple signalling
pathways that repress pol III transcription, research turned towards discovering
the mechanism by which Mafl asserts its repressive activity on pol III.
Upadhya et a l, used treatment of yeast cells with chlorpromazine (CFZ) to
repress pol III transcription and established that this effect was absolutely
dependent on Mafl (2002). To examine the possibility that CPZ-repression of
pol III transcription through Mafl could be due to CPZ-targeting of a
component of the pol III transcriptional machinery, extracts of cells treated
with CPZ were supplemented with partially purified yeast TFIIIB, TFIIIC, or
pol III. Only the addition of TFIIIB, and not TFIIIC or pol III, restored
transcription levels to that of the control extract. These experiments implicated
TFIIIB as the target for repression of pol III transcription by CPZ. Further
biochemical data suggest that CPZ-induced repression of TFIIIB activity
results from a defect in its recruitment to DNA (Desai et a l, 2005). This
established a link between Mafl-dependent transcriptional repression and de
novo assembly of TFIIIB onto DNA (Desai et a l, 2005; Upadhya et a l, 2002).
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More recent experiments performed by Desai et al. further clarified the 
manner in which Mafl acts through TFIIIB to repress pol III transcription 
(2005). By executing supplementation experiments with all three subunits of 
TFIIIB (TBP, Brfl and Bdpl) to CPZ-treated cells, Brfl was found to be the 
target for repression. However, the differential between the control and CPZ- 
treated extracts was lessened, but not eliminated, following the addition of 
Brfl, suggesting that there may be another factor/step affected under 
repressing conditions.
To determine at which assembly point Mafl asserts its repressional activity, 
Desai et a l added Mafl to pre-assembled TFIIIB-TFIIIC-DNA complexes 
(2005). Addition of Mafl did not have an effect on the amount of the TFIIIB- 
TFIIIC-DNA complex. This suggests that the inhibitory effect of Mafl on 
transcription from preassembled complexes involved a post-TFIIIB 
recruitment step. By adding Brfl to mixtures containing Mafl proteins and 
TFIIIC-DNA, it was found that Mafl inhibits B rfl’s recruitment onto TFIIIC- 
DNA complexes. The associations between Mafl, pol III and Brfl did not 
change quantitatively in repressed cell extracts, suggesting that the effect on 
pol III transcription by Mafl is non-stiochiometric. Mafl is not simply 
sequestering away Brfl or pol III from the transcription complex. The data 
above implicate Mafl in a biochemical process that inhibits TFIIIB-DNA 
complex assembly and transcription. Brfl is a likely target of repression in 
yeast, as the activity of Brfl decreased significantly in the TFIIIB fraction 
treated with CPZ (Desai et a l, 2005).
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Inhibition o f pol IIIfunction
Chromatin immunoprécipitation experiments conducted by Oficjalska-Pham et 
al and Roberts et a l discovered a weak association of Mafl with pol III genes 
in exponentially growing cells (2006). Under repressing conditions, the 
association of Mafl and pol III increased with the nuclear concentration of 
Mafl (Oficjalska et a l, 2006; Roberts et a l, 2006). However, levels of the 
polymerase at pol III promoters decreases in a Mafl-dependent manner (Desai 
et a l, 2005; Oficjalska et a l, 2006; Roberts et a l, 2006). These results 
combined are interesting as they lead to two distinct models of the inhibition of 
pol III function. In one model, Mafl is only associated with pol III genes 
ephemerally and its action causes the dissociation of the polymerase. In the 
alternative model, Mafl is stably bound to pol III genes, where its capacity to 
disengage (but not necessarily separate) DNA from the polymerase inhibits 
transcription (Roberts et a l, 2006). Clearly, more efforts are needed to further 
resolve these models.
In summary, Mafl inhibits two distinct steps in transcription: de novo 
assembly of the initiation factor TFIIIB by promoter-bound TFIIIC, and 
transcription from pre-assembled TFIIIB-DNA complexes (Desai et a l, 2005; 
Upadhya et a l, 2002) (these conclusions and those above are summarized in 
Figure 5.2).
5.1.6 Mammalian cells
Mafl was found to be a conserved protein from yeast to humans in early 
studies and it was recently demonstrated that Mafl plays a central role in pol 
III repression of mammalian cells (Pluta et al, 2001; Reina et a l, 2006).
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Paralleling yeast studies, human Mafl was found to bind to Brfl and the 
largest subunit of pol III (RPCl in humans), but was also shown to bind to 
another pol III subunit, RPAC2 (Reina et a l, 2006). Experiments using 
extracts from rapamycin or methanemethylsulfonate (MMS) -treated cells 
incubated with phosphatase inhibitors determined that human Mafl is 
phosphorylated and becomes largely dephosphorylated after stress, the 
dephosphorylated form associating with pol III (Reina et a l, 2006). Therefore, 
yMafl acts similarly to hMafl when taking into account the above binding 
properties and phosphorylation. However, there are a few differences between 
species. Further advancements have also been made, allowing a deeper 
understanding of M afl’s role in mammalian cells.
In human cells, Mafl represses transcription not only from type 1 and type 2 
promoters, but also type III promoters, which are absent in yeast (Reina et a l, 
2006). Mafl did not affect assembly of any of the transcription components 
(i.e. SNAPc, TBP, Brf2 or Bdpl) onto the type III human U6 promoter. Only 
associations with pol III were noted. These results suggest that in mammalian 
type III promoters M afl’s function occurs when it is bound to pol III and does 
not act on the formation of the promoter-bound pol Ill-recruiting complex. 
M afl’s actions on human type I and type II promoters probably parallel that of 
yeast, as human Mafl has been shown to bind to Brfl and it is these two 
promoter types that utilize B rfl.
Reina et a l also examined the regions in which Mafl associates with pol III 
and Brfl (2006). Mafl contains three regions of highly conserved sequences, 
deemed A-, B- and C- boxes, followed by an acidic tail. By generating
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truncated versions of the protein, both pol III subunits (RPCl and RPC2) 
associated with the A box, whereas Brfl only associated with the A- and B- 
boxes of M afl. Thus, pol III and Brfl both need the Mafl A- box to bind, but 
Brfl also needs the additional B- box. This indicates that Mafl interacts with 
pol III and Brfl at overlapping binding domains.
As Mafl was found to be involved in at least two repression pathways in 
humans (DNA damage and mTOR) which directly affect pol III transcription, 
this chapter focuses on the ability of Mafl to repress pol III transcription in 
mammalian cells as another technique to decrease pol III transcription. When 
these experiments were performed, the information contained within this 
chapter was yet unpublished; however, similar work Is now published within 
Reina et ah, although this chapter does contain select novel results (2006).
5.2 Results
5.2.1 Induction of M afl represses pol III transcription in 
human cells
To study the effect of overexpressing Mafl in cervical carcinoma (HeLa) cells, 
I created a Mafl-inducible HeLa cell line using the BD™ Clontech Tet-On 
system (hMafl cDNA acquired from Olivier Lefebvre, Saclay, France). Mafl 
was tagged with hemagglutin (HA) by sub-cloning hMafl into pCDNA3HA 
for better visualization by Western blot. Experimental (pTRE2.HA.Mafl .hyg) 
and control cells (pTRE2.hyg) were induced with 1 mg/ml doxycycline and 
harvested after 48 hours for both RNA and protein extracts. cDNAs were 
prepared from the RNA to utilize in PCR analysis, while the protein extracts
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were analysed in SDS-PAGE gels followed by Western blotting. RT-PCR 
results showed decreases in pol III transcripts tRNA'^ ®“ (although very slight in 
II and 12) and 5S rRNA , although the decreases in 5S rRNA levels were not 
as significant and also varied (discussed below) (Figure 5.3A, panels 2 and 3). 
As expected, Mafl mRNA was increased in the pTRE2.HA.Mafl.hyg cells 
when compared with the control cells (Figure 5.3A, panel 1). The effect of 
Mafl in these cells is specific for pol III, as there was no change in the level of 
the class II gene product ARPP PO mRNA (Figure 5.3A, panel 4). To 
determine if induction of Mafl mRNA was also influencing the level of Mafl 
protein, and therefore translation, protein extracts were run on SDS-PAGE gels 
and immunoblotted with an antibody against Mafl (FB-1167), as well as an 
anti-HA antibody. Indeed, both the exogenous (detected by the anti-HA 
antibody) and endogenous levels (detected by the FB-1167 Mafl antibody) of 
the Mafl protein increased in concordance with the RT-PCR results (Figure 
5.3, B and C). An anti-Spl antibody (Figure 5.3 B and C, lower panels) is 
used as a loading control. Within the cell, Spl functions as a transcription 
factor, the protein running at approximately 95 kDa on an SDS-PAGE gel. 
This experiment demonstrates that the induction of Mafl in a stable human cell 
line represses pol III transcription.
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Figure 5.3 Induction of Mafl represses pol III transcription in 
human cells
A. HeLa pTRE2.hyg and pTRE2.HA.Mafl.hyg. cells were plated in 10 
cm culture dishes and grown under normal conditions for 24 hours. Half 
the cells were then induced with 1 mg/ml doxycycline and incubated for 
a further 48 hours, while the other half received fresh media only. At 
this point cells were harvested for RNA extracts and RT-PCR was 
applied. Mafl, tRNA^^", 5s rRNA, and ARPP PO were analyzed. “C” 
stands for the control cell line pTRE2.hyg, while “I” stands for the 
inducible cell line pTRE2.HA.Mafl .hyg. symbolizes uninduced and
induced. These results are representative of three separate 
experiments.
B. Cell extracts were also made from uninduced and induced cells, 
above. Lysates were subjected to SDS-PAGE analysis and then 
immunoblotted with either antibody against endogenous Mafl (FB- 
1167) or loading control Spl. These results are representative of two 
separate experiments.
C. The same cell lysate from (B) was ran on a separate SDS-PAGE gel 
and immunoblotted with either HA antibody, to detect the HA-tagged 
Mafl, or Spl, used as a loading control. These results are representative 
of tliree independent experiments.
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As previously shown, decreasing pol III transcription by using siRNA targeting 
of Brfl in mammalian cells decreases proliferation rates {Chapter 3, Figures 
3.4 and 3.6). Therefore, one might postulate that decreasing pol III 
transcription by inducing Mafl might have the same affect. The same clones 
(as above) were induced for 96 and 120 hours, and cell numbers were counted. 
When compared to the empty vector cells, the inducible cells overexpressing 
Mafl ended at 120 hours with fewer cells (Figure 5.4, bar set C+, compared 
with bar sets II+, 12+ and I3+).
The inducible cells all have a proliferation rate that is ~ 2 fold less than that of 
the empty vector cells. However, when inducible clones are compared as non­
induced and induced (such as II- compared with I1+), only the II clone seems 
to have a reduced proliferation rate at 120 hours. The other clones, 12 and 13 
have almost equal proliferation rates as each time point, non-induced and 
induced. The proliferation data does not correlate with the RT-PCR and 
Western blotting analysis, as one would expect the clones with higher 
expression levels, 12 and 13, to produce the largest decreases in proliferation 
rates.
These results maybe at least partially explained by the fact that these inducible 
cell lines have leaky expression (i.e. a high background). This is apparent 
when non-induced cells are compared with induced cells in all clones, as non­
induced cells still have a relatively high level of expression (Figure 5.3A, B 
and C, lanes 3, 5 and 7).
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Figure 5.4 Expression of M afl in HeLa cells leads to variable proliferation 
rates
Cells were induced and counted at 0 hours, 96 hours and 120 hours after equal 
plating on 10 cm dishes and induction by 1 mg/ml doxycyclin. Results are 
representative of two separate inductions.
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The only exception to this may be clone II, as the signal of the non-induced 
clone is not apparent and there is a signal for the induced clone (Figure 5.3C, 
lane 3, compared to lane 4). However, increased exposures time of this film 
showed a slight background level as well, demonstrating that this clone also 
lacks tight regulation. This also explains why the levels of pol III transcripts 
were not as decreased as expected. In a system such as this with high 
background, levels of pol III transcripts of induced cells will not appear as 
decreased as they would if the system was under tighter control. The loose 
control of this Mafl-inducible system was not due to the presence of 
doxycycline in the media, as Tet system approved FBS (BD Biosciences 
Clontech) was used. Levels of the tRNA^®“ transcript appear to be affected 
more than 5S rRNA as the primers for tRNA^®“ are designed to monitor 
actively produced transcripts, while the 5S rRNA primers show steady state 
levels. Further screening experiments were performed to try and discover 
clones which had lower background, but to no avail. Therefore, more direct 
and less laborious approaches were commenced to look at the effects of Mafl 
on pol III transcription.
5.2.2 Endogenous M afl inhibits pol III transcription in human 
and mouse cells
As discussed in Chapter 3, siRNA can be a useful tool for gene knockdown, 
and it is this technique that was employed to decrease pol III transcription by 
targeting Mafl in HeLa cells. Cells were nucleofected with 3 pg of siRNA 
duplex, plated, and harvested 48 hours later for RNA. cDNAs were made from 
the RNA and PGR analysis was completed to determine mRNA levels.
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As expected, Mafl mRNA levels were decreased in the cells treated with Mafl 
siRNA when compared to Mafl mRNA levels in cells treated with control 
siRNA (Lamin A/C) (Figure 5.5, top panel). Levels of pol III transcript 
tRNA^®“ were increased, reflecting the function of Mafl as a repressor, as 
decreases in Mafl would relieve pol III of repression by Mafl, increasing 
transcription and therefore pol III transcripts. Paralleling that of the above 
experiment (Figure 5.3), levels of 5S rRNA showed an increase of a lesser 
degree, reflecting the fact that these PCR primers are recognising a stable 
transcript. These results are specific, as there is no change in the pol II gene 
product ARPP PO (Figure 5.5, last panel).
By knocking down Mafl with specific siRNA, pol III repression by Mafl is 
released, increasing pol III transcription. This method directly targeted and 
reduced Mafl levels within the cell, providing a “pseudo-Mafl knockout.” To 
extend these results, extracts were harvested from a mouse embryonic stem 
(ES) cell line which had one mafl allele deleted (obtained from Olivier 
Lefebvre, Saclay, France). cDNAs were made from RNA and RT-PCRs were 
performed to detect pol III transcription. Increased expression of pol III 
transcripts tRNA^^ and 5S rRNA was demonstrated, although there was little 
change in tRNA^^" (Figure 5.6). The reason why tRNA^^" did not change is 
unclear. Mafl mRNA expression is diminished in the heterozygous cells 
compared with the homozygous cells, consistent with the expression of only 
one allele. Figures 5.5 and 5.6 combined show that by depleting Mafl by 
using siRNA or by deleting one Mafl allele, pol III transcriptional output is 
increased.
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Figure 5.5 siRNA targeting Mafl inhibits pol III 
transcription in HeLa cells
HeLa cells were transfected by electroporation with 3 pg 
siRNA targeting either Lamin A/C (control) or Mafl 
mRNAs. 48 hours post transfection, RNA was extracted 
and analysed by RT-PCR using the gene-specific primers 
Mafl (panel 1), tRNA^®“ (panel 2), 5S rRNA (panel 3), and 
ARPP PO (panel 4). Results are representative of three 
independent experiments.
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Figure 5.6 Endogenous Mafl inhibits pol III 
transcription in mouse cells.
RNA was analysed from matched Mafl^ or 
Mafl ES cells by RT-PCR using primers for Mafl 
(panel I), B2 (panel 2), tRNA' '^^8(panel 3), tRNA^®“ 
(panel 4), 5S rRNA (panel 5) and ARPP PO (panel 
6). Results are representative of three independent 
experiments.
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5.3 Discussion
The methods described above were ail successful in affecting pol III 
transcription by either increasing Mafl levels within the cell using an 
inducible cell line or by decreasing Mafl levels by utilizing siRNA or by 
deleting one allele. Depending on the information that one is looking for, 
different techniques might be used for different experiments to optimize 
results. For example, using an inducible cell line is clearly more beneficial 
than using siRNA when proliferation rates are the aim of the study. Inducible 
cell lines often allow long-term phenotypes to be observed, which may not be 
possible when adding synthetic siRNAs, as turnover rates may vary and 
therefore repeated transfections may be necessary. Inducible cell lines have 
problems as well, when long-term expression of an essential protein kills the 
cell, or when expression systems are loosely regulated (as above). The 
production of knockout mice is labour extensive and not always possible, but if 
achieved, the knowledge from knockout or even heterozygous cells is 
invaluable. Recently, experiments conducted by Johnson et a l showed a 
correlation between the overexpression of Mafl and the suppression of 
anchorage-independent growth (a hallmark of transformed cells) (2007). 
Ideally, it would have been interesting to perform anchorage-independent 
growth assays on the Mafl Tet-On inducible cells, but again, these cells would 
need to be selected again for minimal background expression levels.
Taken together, the results in this chapter have shown that induction, 
suppression and deletion of Mafl affects pol III transcription in mammalian 
cells. Mafl was proved to be a potent general repressor of pol III transcription 
in mammalian cells by three different techniques.
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6.1 Small interfering RNA targeting Brfl decreases RNA 
polymerase III transcription
In Chapter 3, pol III transcription was decreased by transfecting HeLa cells 
with siRNA targeting TFIIIB subunit B rfl. Brfl was previously shovm to bind 
directly to TBP, TFIIIC and pol III, making it an instrumental component of 
the basal pol III transcription apparatus (Hsieh et a l, 1999b; Hsieh et a l, 
1999a; Kassavetis et a l, 1992; Kassavetis et a l, 1998). Brfl was also found to 
be an influential binding site for tumour suppressors, oncogenes and kinases, 
further stressing the significance of Brfl as a hub for influencing pol III 
regulation within the cell (Crighton et a l, 2003; Felton-Edkins et a l, 2003a; 
Gomez-Roman et al., 2003; Johnston et a l, 2002; Larminie et a l, 1997; 
Schmidt, 1999).
siRNA technology has been an innovative and invaluable research tool since 
its discovery and applications within mammalian systems have made it more 
applicable in the study of human disease. The proper controls when using 
siRNA are of the utmost importance; the level of significance of the results 
relies heavily upon this and control standards within the field must be 
monitored and updated regularly. Although the mechanism behind siRNAs 
effectiveness lacks some understanding, future experiments might clarify 
present knowledge, and perhaps even change the types of controls used. With 
proper controls in place, siRNA proves to be a powerful research tool in 
mammalian systems.
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Using Brfl siRNA to decrease pol III transcription in vivo proved to be 
successful within the experiments contained in Chapter 3. Although controls 
could have been more stringent (discussed on pages 48-51, 62), sufficient 
controls were in place to deduce that the Brfl siRNA was depleting the cells 
production of Brfl mRNA and protein (Figures 3.3A and 3.3B). Further 
analysis showed that the reduction of pol III transcripts in response to this 
silencing affected the cell’s ability to proliferate at a normal rate (Figures 3.4 
and 3.6). This result is substantial, as one of the classifications of cancer 
involves unchecked proliferation and therefore decreasing proliferation rates 
may provide insight into growth controls. An increase in pol III transcription 
has been linked to many types of cancers, therefore the reduction of B rfl, and 
hence pol III transcription, may provide not only a valuable research tool, but 
also a glimpse into possible therapeutics.
6.2 Tagetitoxin decreases RNA polymerase III 
transcription in mammalian cells
Past studies found tagetitoxin to be a potent and specific inhibitor of pol III 
transcription and that this inhibition was due to enhanced pausing at isolated 
sites and was template-dependent (Steinberg and Burgess, 1992; Steinberg et 
a l, 1990). Tagetin'^’^ , the commercially available form of tagetitoxin, was 
used in the experiments contained in Chapter 4, to attempt inhibition of pol III 
transcription in mammalian cells by in vivo application. When applied to 
mouse cells by direct application, pol III transcripts did not decrease (Figures 
4.2A, or decreases were unexplained when compared to other transcripts which 
did not decrease (Figure 4.2A). Using heat shock to induce membrane pores
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possibly allowed tagetitoxin to repress pol III transcription, but the unknown 
effects of heat shock would make this technique unreliable (Figure 4.3). 
Treatment of human cervical cells with tagetitoxin by electroporation was the 
most successful attempt at decreasing pol III transcription in vivo.
There is not a great quantity of research that has been published to date of the 
successful introduction of a drug in mammalian systems via electroporation, 
although the research seems promising (Bleomycin, 2004; Hui, 2002; Kambe 
et a l, 2006). Electroporation has been used to introduce anti-cancer drugs 
across the skin, although further research needs to occur to perfect this 
technique as the optimal conditions such as voltage, along with problems 
caused by the size of the drug, are difficult to discern (Hui, 2002). 
Electroporation holds the most promise for further research with tageitoxin in 
the laboratory, although the method of application will limit its uses. For 
example, long-term studies of cells treated with the inhibitor would be difficult 
as the amount of cells used during transfection with the nucleofector is quite 
high and therefore confluency is reached by 48 hours. If the cells were split 
into a larger vessel they would possibly need to be treated again, with both 
tagetitoxin and nucleofection, and this treatment might prove toxic. 
Nevertheless, if a technique was found to successfully apply tagetitoxin 
directly to culture media, then long-term effects on targeting pol III 
transcription could be observed. It would be interesting to perform 
proliferation curves with tagetitoxin in transformed cells, to see if the effect 
mimicked that of the proliferation curves in Chapter 3. If the proliferation 
rates were also decreased by tagetitoxin it would hint at possible therapeutic 
options for cancers that show an increase in pol III transcription.
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6,3 Targeting Mafl by silencing, deletion and induction 
influences pol III transcription
Mafl is a common component of multiple signalling pathways that affect pol 
III transcription (Upadhya et a l , 2002). Research has recently uncovered some 
of the mechanisms behind these pathways, and the manner in which Mafl 
represses pol III transcription. Nuclear localization, phosphoregulation, and 
direct targeting of TFIIIB subunit Brfl are characteristics that apply to M afl’s 
repressive influence over pol III transcription (Murawski et a l, 1994; Moir et 
al, 2006; Pluta et a l, 2001; Roberts et a l, 2006; Upadhya et a l, 2002). 
Although most of the knowledge of M afl’s repressive nature was acquired in 
experiments performed in yeast, current work also includes at least a partial 
understanding of the mechanism of Mafl in mammalian systems.
The induction of Mafl in a stable cell line decreased pol III transcription, but 
to varying degrees {Chapter 5, Figure 5.3A). This was probably due to the 
leaky nature of the stable cell line. Perhaps some of the cells were not killed 
off by selection and therefore created a high background Mafl signal. 
However, this seems unlikely as the drug used for selection was used at a high 
concentration and therefore the cells would have to adapt to these high levels. 
The control for resistance to the selection drug (hygromycin), and the induction 
drug (deoxycyclin), were located on the same plasmid within the cell, making 
it improbable that the leakiness was do to the loss of one plasmid. The results 
of the proliferation curve reflect the loose control of Mafl expression by these
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cells (Figure 5.4). In order for any deductions to be made with confidence, 
cells with a tighter control of Mafl expression would have to be created.
The experiments focusing on the silencing and deletion of Mafl were more 
successful. siRNA targeting Mafl in HeLa increased pol III transcription, 
releasing the transcription apparatus from repression (Figure 5.5), while the 
deletion of one mafl allele from ES cells also positively affected transcription 
(Figure 5.6). Combined, these data provide further evidence that Mafl 
represses pol III transcription in two different mammalian cell types.
6.4 Final synopsis
Three different methods were attempted to decrease pol III transcription in 
mammalian cells; small interfering RNA against Brfl, treatment with the 
specific pol III inhibitor tagetitoxin, and the induction of a negative effector of 
pol III transcription, Mafl. These techniques vary considerably, and even the 
matter in which each individual technique was applied differed (i.e. the direct 
application of tagetitoxin versus nucleofection, etc.). Whatever the case, each 
technique has both desirable and disadvantageous qualities.
Finding techniques for decreasing pol III transcription has importance as pol 
III transcription has been found to be increased in a variety of cancers. Even a 
subunit within the transcription apparatus, Brfl, has been found to have 
increased levels in cervical cancer tissue. Pol III is also able to influence a 
cell’s biosynthetic capacity, which must be increased for cell growth and 
proliferation. Clearly, transcription by pol III has an important role in the 
outcome of a cell toward normal or transformed growth. Therefore,
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discovering techniques which decrease pol III transcription in mammalian cells 
is beneficial not only for further knowledge in mechanistic purposes but could 
also be a useful tool as therapeutics for the future.
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